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ABSTRACT OF DISSERTATION

TARGET VALIDATION OF UK-101 AND FUNCTIONAL STUDIES OF β1i
β1i is a major catalytic subunit of the immunoproteasome, an alternative form of the
constitutive proteasome, and its upregulation has been demonstrated in a variety of disease
states including cancer. Our lab has developed a small molecule inhibitor of β1i, dubbed UK-101.
While UK-101 causes apoptosis in cancer cell lines, it was not clear whether this apoptotic effect
was directly mediated by its irreversible inhibition of β1i. Since off-target effects are major
roadblocks for the development of new and effective pharmaceuticals, target validation studies
in this system would assist in the further progression of β1i inhibitors towards preclinical trials.
Our hypothesis was that the expression and catalytic activity of β1i is important for the growth
and proliferation of the PC-3 prostate cancer cell line, therefore the apoptotic effect seen upon
treatment of PC-3 cells with UK-101 was due solely to its covalent inhibition of β1i.
To test this hypothesis, a number of complementary approaches were used. The
expression of β1i in PC-3 cells was increased by the treatment of these cells with interferongamma or tumor necrosis factor-alpha, natural inducers of the immunoproteasome. The
expression of β1i in PC-3 cells was decreased using small interfering RNA or short hairpin RNA, in
a transient or stable manner, respectively. All of these cells were then treated with UK-101.
The efficacy of UK-101 decreased in the interferon-gamma treated cells but did not change in
any other the other cell lines, suggesting that UK-101 was not specific for β1i. This was
confirmed using a molecular probe of the proteasome and demonstrated that UK-101 bound to
other proteasome catalytic subunits.
Additional experiments were performed to determine the effect of β1i on the
proliferation of PC-3 cells. Simply removing the β1i using small interfering RNA reduces the
viability of these cells. Other studies demonstrated that a mutation of β1i which inhibited its
catalytic activity reduced the viability of cells when compared to those containing the wild type
protein. Overall, our data indicate that β1i is a potential therapeutic target in prostate cancer.
Further medicinal chemistry efforts will be required develop UK-101 into a truly selective
proteasome inhibitor.
KEYWORDS: Immunoproteasome, Target Validation, β1i, UK-101, proteasome inhibitor (Include
exactly 5 keywords or phrases)
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Chapter 1: Introduction
A: Intracellular proteolysis and the ubiquitin-proteasome pathway
Scientists spent much of the 1900s studying the flow of genetic information into proteins,
building up the evidence for what is now known as the “central dogma of molecular biology.”
Prior to 1950, few scientists were concerned with the destruction of proteins, as most believed
intracellular proteins to be extremely stable and resilient. The lysosome, discovered in the
1950s, was thought to provide cells with the necessary destructive capacity. Over the next two
decades it became increasingly difficult to reconcile the mechanistic understanding of lysosomal
degradation with the turnover of intracellular proteins, especially those that were short-lived or
abnormal. It was also found that much of this intracellular protein turnover required adenosine
triphosphate (ATP), in direct conflict with the mechanism of action of lysosomes.
Work done in the early 1980s by Aaron Ciechanover, under the direction of Avram Hershko and
his collaborator Irwin Rose, led to “the discovery of ubiquitin-mediated protein degradation” for
which the trio received the 2004 Nobel Prize in Chemistry. [1] Their work explained the ATPdependency of intracellular protein degradation by demonstrating that proteins are degraded
more effectively when tagged with a protein called ubiquitin. A three-enzyme cascade was
discovered which adds ubiquitins to proteins in a specific and ATP-dependent manner (Figure
1.1). The ubiquitin-activating enzyme class (E1) uses ATP to charge and transfer ubiquitin to a
second enzyme class, the ubiquitin carrier proteins (E2). These E2 enzymes associate with the
third class of enzymes, the ubiquitin protein ligases (E3), which can add ubiquitin molecules to
proteins in a substrate-specific manner. Likewise, later work discovered an additional class of
enzymes, called deubiquitinases (DUBs), which can remove ubiquitin moieties from proteins and
thus further regulate the pathway.
The next critical step was to determine the protease responsible for the eventual degradation of
these ubiqutinated proteins. By the end of the 1980s, many of the leaders in this young field of
protein degradation believed the proteasome might be the ATP-dependent protease which
recognizes and degrades ubiquitinated proteins. This complex was first described by S. Wilk and
M. Orlowski in the early 1980s and was then known as the multicatalytic protease complex
(Figure 1.1). [2, 3] The multicatalytic protease complex, or proteasome, was a ~700kDa complex
found in electron microscopy studies to be a hollow, cylindrical structure composed of four
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Figure 1.1: The ubiquitin-proteasome pathway. A protein is tagged by multiple ubiquitin
molecules (green circles) by a series of enzymes: E1s, E2s, and E3s. The proteasome recognizes
these polyubiquitinated substrates, binding, deubiquitinating, unfolding, and degrading the
proteins. Short peptide fragments are released by the proteasome to be further degraded by
intracellular proteases or used in antigen presentation.
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stacked rings. [4] It was proposed to have a variety of protease activities: chymotrypsin-like (CTL), caspase-like (C-L), trypsin-like (T-L), branched chain amino acid preferring (BrAAP), and small
neutral amino acid preferring (SNAAP). [3, 5, 6]
The importance of the proteasome for normal cell survival was indicated by studies in
Drosophila melanogaster which identified a mutation in a proteasome subunit as a dominant
temperature-sensitive lethal mutation. [7, 8] Later studies showed an additional proteasome
subunit mutation with the same dominant temperature-sensitive lethal effect; both mutations
function as “poison subunits” which affect the stability and activity of proteasomes at increased
temperatures. [8, 9] Additionally, studies in hematopoietic cells from leukemia patients as well
as malignant hematopoietic cell lines showed increased expression of proteasomes in a variety
of cancers (acute lymphoblastic leukemia [ALL], adult T-cell leukemia [ATL], acute myeloid
leukemia [AML], chronic lymphocytic leukemia [CLL], chronic myelogenous leukemia [CML], and
Burkitt lymphoma). [10] The authors suggested that, “Thus, abnormally high expression of
proteasomes may play an important role in transformation and proliferation of blood cells and
in specific functions of hematopoietic tumor cells.” [10]
To determine the intrinsic and adaptive function of this complex, probes of its activity would be
required. Luckily, biochemists that studied the bovine multicatalytic protease complex had
developed substrates for its main proteolytic activities: CT-L, C-L, and T-L. The CT-L activity,
cleaving after large, hydrophobic amino acids, is now most commonly examined using Nsuccinyl-leucine-leucine-valine-tyrosine-7-amino-4-methylcoumarin

(Suc-LLVY-AMC),

where

cleavage after the tyrosine liberates AMC. This cleavage can be observed by excitation at
360nm, allowing for detection of the emission wavelength at 460nM. Likewise, the C-L activity,
cleaving after acidic amino acids, is now detected using benzyl-norleucine-proline-norleucineaspartame-AMC (Z-nLPnLD-AMC) and the T-L activity, cleaving after basic amino acids, is now
detected using benzyl-leucine-arginine-arginine-AMC (Z-LRR-AMC). A number of additional
substrates have been developed over the years, but these are considered the prototypical
substrates for proteasomal hydrolysis.
This method of examining proteasome activity provides a limited amount of useful information.
As Peter Kloetzel and colleagues noted in 1995: “We conclude that the hydrolysis of short
fluorogenic peptides does not adequately describe the cleavage of peptide bound in larger
peptides by the 20S proteasome and that the decision on the cleavage site … is not simply
3

dependent on the residue in the P1 position.” [11] Nevertheless, this technique remains a
popular one to describe proteasome activity.
To better understand the role of this protease complex in normal and disease states, inhibitors
of this complex which could be utilized to conclusively determine its function would be required.
Marian Orlowski and colleagues produced the first peptide aldehydes (Z-LLF-CHO, Ac-LLnL-CHO,
and Ac-LLM-CHO) which inhibited the CT-L activity of the bovine multicatalytic protease complex
as slow-binding, reversible inhibitors. [12] At higher concentrations, these small molecules were
also found to inhibit the T-L and C-L activities of the complex, providing biologists with the final
tools necessary to examine the proteasome hypothesis. [12] In 1994, Alfred Goldberg’s group
published a paper in Cell entitled, “Inhibitors of the proteasome block the degradation of most
cell proteins and the generation of peptides presented on MHC class I molecules.” [13] For the
first time, they showed that the majority of cellular proteins were degraded by the proteasome
and that this pathway was important for the proper functioning of the immune system, as it
created the peptides necessary for major histocompatibility complex (MHC) class I molecules.
[13] Thus began a flurry of work to further define and examine the proteasomal structure,
assembly, activities, and functions.
B: Proteasomes and their catalytic beta subunits
Mammalian proteasomes are now known to contain catalytic beta subunits which degrade
polypeptides. Early studies examined these protein sequences and hypothesized that these
subunits may be synthesized as precursors, and later processed to the active form, likely by
cleavage at Gly-1/Thr1 leaving an N-terminal threonine to serve as a nucleophile. [14] At least
two proteolytically active subunits were known at the beginning of the 1990s, which we now call
Y/β1 and X/β5. Around this time, a second set of proteins named low molecular mass proteins
two and seven (LMP2 and LMP7) were characterized by sequence alignment; they were
hypothesized to be proteolytic subunits, also synthesized as precursor proteins but present in
processed forms in intact proteasomes. [14-16] These LMP proteins were found as gene pairs,
with LMP2 and antigen peptide transporter 1 (TAP1) or LMP7 and TAP2 in close proximity. [17]
TAPs are ATP-binding cassette (ABC) transporters which take peptides from the endoplasmic
reticulum (ER) to the cell surface for class I antigen presentation. By looking at sequence
homology and exon/intron pairing, the authors concluded that LMP7/TAP2 was the original
gene pair, duplicated to produce LMP2/TAP1. [17] These genes are well conserved, as the
4

cluster originated prior to the human/mouse/rat species divergence, with LMP2 sharing 84%
DNA sequence and 88% protein sequence homology between humans and mice. [17] Both gene
pairs have putative interferon-stimulated response elements in their promoter regions, and
their expression is stimulated by interferon experimentally. [11, 16-23]
Further studies of the LMP proteins found they were able to replace the “constitutive”
proteasome subunits. LMP2 replaced β1 and LMP7 replaced β5, thus current nomenclature
calls them β1i and β5i, respectively. [22] Interestingly, β1 and β1i only share 76% sequence
similarity, but their expression levels seemed to be inversely correlated. [22, 24] Experiments
were undertaken to determine what changes may occur when one set of subunits was replaced
by the other. They found that adding β1 to cells increased the C-L activity but did not affect the
T-L or CT-L activity, while adding β5 decreased the CT-L and T-L activity but had no effect on the
C-L activity. [24] Conversely, the addition of β5i increased the T-L and CT-L activity, while not
affecting the C-L activity; the addition of β1i decreased the C-L activity and increased the T-L
activity, but did not affect the CT-L activity. [21, 24, 25] Notably, adding β5 increased expression
of β1, and vice versa, suggesting these subunits incorporate into proteasomes cooperatively.
[24]
The activity change seen above paired with the proximity to the TAP genes, lead many to
theorize that these LMP subunits may form a different kind of proteasome, which was dubbed
an immunoproteasome, to produce antigens for MHC class I presentation.

MHC class I

molecules are found on all nucleated cells and function to display small, internally produced
peptides to T cells. If the peptides presented on the cell surface contain foreign proteins, known
as antigens, the cell will be attacked by the immune system; otherwise, the cell is ignored. It
had been shown that the TAP proteins were required for antigen presentation by MHC class I
molecules. [26, 27] However, work by a number of researchers quickly showed that these
alternative catalytic subunits are not obligatory for antigen presentation by MHC class I
molecules. [19, 21, 26-28] Still, some suggested that immunoproteasomes may alter the
spectrum of peptides produced or amplify specific proteolytic activities favorable for antigen
presentation. [19, 21, 25, 27, 29] Nevertheless, the vast majority of peptides presented by MHC
class I molecules are generated by some form of the proteasome. [30]
Further studies of the LMP subunits found that their expression could be induced by treatment
with interferon-γ. [22] This work demonstrated that interferon-γ causes the expression of the
5

“inducible” proteasome subunits (β1i and β5i), thus the increase in the inducible subunits led to
a decrease of proteasomes containing the constitutive subunits. [22] However, the amount of
β1i present in a cell after treatment with interferon-γ increases to varying degrees in a cell linedependent manner. [28] Transfection of β1i and β5i likewise mimic the changes in proteolytic
activity and products produced by treatment of cells with interferon-γ, strongly suggesting that
interferon-γ produces these changes by upregulating these two proteins. [21] Knocking out
signal transducer and activator of transcription 1 (Stat1) reduces the constitutive expression of
immunoproteasome subunits, suggesting it might play a major role in their normal expression.
[31] Thus, it is important to note that interferon-γ is essential for upregulation of
immunoproteasome subunits, but not their constitutive expression. [31]
Not long thereafter, the third pair of exchangeable subunits was identified: β2/Z and β2i/MECl1/LMP10. [32-34] Like the other inducible beta catalytic subunits, β2i can replace β2 in humans
and mice, the β2i gene shares 89% identity between the species, and β2i is inducible by
treatment with interferon. [32-37]

Interestingly, the size of the β2i and β2 genes differ

significantly, although both have eight exons and equivalent exon-intron boundries, suggesting
they likely arose by duplication from a common ancestor. [36] Later studies which examined β2
found that its expression levels, like those of β1, increased upon β5 overexpression. [38]
Additionally, a mutation of β2i which abrogates its catalytic activity causes loss of T-L activity,
which is not a required proteasomal activity in rabbit tissues. [39, 40]
As demonstrated above, the beta subunit genes are scattered throughout the genome,
suggesting the stabilization of these proteins by incorporation into proteasomes; this would
permit the rapid turnover of unincorporated subunits and provide a mechanism by which the
subunits could be regulated in a cooperative manner. [41] In addition, studies show that the
MHC class I expression deficiencies of a number of tumor cell lines could be overcome by
treatment with interferon-γ. [42, 43] This implies that such alterations in the protein expression
patterns of malignant cells are due to regulatory or epigenetic changes, rather than direct
genetic mutations.
Additionally, the net effect of the incorporation of these inducible subunits in proteasomes may
depend on the overall proteasome beta catalytic subunit composition in a cell or tissue. [44]
With regard to the these proteins, it has been found that high mRNA levels do not always
correlate with high protein levels, and the expression of β1i and β5i at the protein level varies
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substantially between cell lines and tissues. [15, 28, 45, 46] In mice, the mRNA levels of β1i and
β5i are high in the thymus, spleen, and lung but absent in the brain and muscle, while protein
expression is highest in the spleen. [15, 47] Likewise, β1i and β5i are constitutively expressed in
all thymic antigen presenting cells in perinatal rats. [48] Moderate mRNA and protein levels of
β1i and β5i are seen in mouse liver, kidney, and heart; in general, β1i and β5i are evenly
distributed between the cytoplasm and nucleus in mouse liver. [15, 47, 49] Interestingly,
treatment with interferon-γ can induce immunoproteasome subunit expression in
immunoprivileged organs of mice, such as the lens of the eye and the brain. [46, 50]
In humans, the inducible subunit β1i mRNA levels are undetectable in fibroblasts, as well as
smooth muscle, colon epithelial, and brain cells. [16] β1i was not found in fetal livers and β5i
was seen in only one-third of the samples examined. [51] However, β1i and β5i were seen in all
adult liver samples at varying intensities. [51] Moreover, β1i, β2i, and β5i are expressed in
human fetal and adult thymal tissues such as the stroma, epithelium, and macrophages of the
cortex and medulla, but not in immature thymocytes. [52] A C-terminal tagged version of β1i
(LMP2-GFP) was found to be incorporated efficiently in proteasomes located through the
cytoplasm and nucleus of human fibrosarcoma cells. [53]
C. Crystallographic and structural studies of proteasomes
Thermoplasma acidophilum is an archaebacterium which contains a very primitive form of the
proteasome. This was ideal for the initial studies of proteasomal crystal structure because of its
simplicity, yet this archaebacterial proteasome was similar enough to be used to model the
proteasomes of eukaryotes. Its proteasome contains two distinct subunits, called alpha and
beta, which are composed of a core of two five-stranded antiparallel beta sheets with three
alpha helices above and two below. [54] The alpha and beta subunits have significant sequence
homology, suggesting they probably evolved from a common gene. [54] The crystal structure of
the T. acidophilum proteasome depicts a complex with 72 point symmetry, a molecular weight
of 673 kDa, and the barrel shape seen in earlier electron microscopy experiments. [54] There are
four rings, two alpha rings on the ends with seven subunits each and two beta rings in the
center, also with seven subunits each. [54]

The alpha subunits contain two putative nuclear

localization sequences which were shown to be accessible to solvent in the crystal structure.
[54] Additionally, the tight packing of the barrel structure should prevent access to the catalytic
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core from any location other than the central channel, where the disordered N-termini of the
alpha subunits could permit the entry of polypeptides. [54]
Interestingly, the first eleven residues of the beta subunits were not present in the crystal
structure, but Lys33 and Glu17 create a salt bridge in close proximity to Thr1, which may form a
catalytic triad. [54] These first eleven amino acids are known as the propeptide of the beta
subunit, and their loss is necessary to produce a catalytically active subunit. Later studies
indicated that these beta catalytic subunit propeptides are not required for the assembly of the
T. acidophilum proteasome. [55] Treatment of proteasomes with the aldehyde inhibitor Ac-LLnLCHO modified all of the beta subunits by formation of a hemiacetal with Thr1, but did not cause
a conformational change in the protein. [54] Mutational studies showed that while Thr1Ala1
mutants do not bind the proteasome inhibitor NLVS (4-hydroxyl-5-iodo-3-nitrophenyl acetateleucyl-leucyl-leucine vinyl sulfone), Thr1Ser1 mutants did, suggesting the side chain hydroxyl of
the first amino acid is important for the proteolytic function of these proteins. [56]
With this structure in hand, scientists next examined the yeast proteasome crystal structure.
They found a similar quaternary structure when compared to the T. acidophilum proteasome,
with four stacked rings but only two-point symmetry. [57] This reduction in symmetry is due to
the existence of seven distinct alpha subunits and seven distinct beta subunits in yeast, which
have the same secondary structure as seen in T. acidophilum, but form rings containing one
copy of each distinct subunit (α1-7/β1-7/β1-7/α1-7). [57] Structurally, these proteasome subunits
resemble N-terminal nucleophile hydrolases (Ntn-hydrolases). [57]
In yeast, only three of the subunits in each beta ring have catalytic activity, as demonstrated by
their binding to Ac-LLnL-CHO at the Thr1 hydroxyl: β1 (Pre3), β2 (Pup1), and β5 (Pre2). *19+ The
propeptides of these catalytically active subunits are processed between Gly-1 and Thr1, with loss
of Thr1 abrogating the proteolytic activity of the subunit. [57-60] Mutation of the Thr1 to Ser1
can maintain proteolytic activity, but, unlike in T. acidophilum, this decreases the cellular
viability of yeast. [59] While the propeptides of β1 and β2 are not required for proteasome
assembly, the propeptide of β5 is necessary for proper incorporation of the subunit, although it
can function in trans with reduced efficacy to rescue β5 propeptide deletion mutants. [58, 6163] Interestingly, it appears that the propeptides of β1 and β2 protect the N-terminal catalytic
threonine against acetylation by Nat1-Ard1; acetylation blocks the enzymatic activities of these
subunits. [62-64] Next, the proteolytic activity of each of these catalytic beta subunits was
8

examined. Mutational studies indicated that β1 had C-L activity, β2 had T-L activity, and β5 had
CT-L (perhaps also some T-L) activity, but only the loss of β5 activity had a significant effect on
cell viability and increased the levels of proteasomes present in cells. [57-62] Another group
suggested that BrAAP activity could be assigned to both β1 and β2. [60]
Unlike the T. acidophilum proteasome, the other beta subunits in the yeast proteasome are
catalytically inactive. β3 and β4 are not processed, while processing of β6 and β7 by their
catalytically active neighboring subunit leaves an eight to ten amino acid cap at the N-terminus;
the processing of β1, β2, and β5 occurs via intrasubunit autolysis and only requires dimerization
of the proteasome halves. [57, 61, 64] β7 is important for this dimerization process, as its Cterminal tail interacts with the other half proteasome to bring the two together in the proper
alignment. [65] Nevertheless, all subunits are important, and mutations in any can be
detrimental, as failure in assembly or processing is often more harmful to cells than proteolytic
inhibition. [61] The makeup of the substrate binding pocket is dependent on residue 45, found
at the bottom of the binding pocket; however, adjacent subunits of the beta ring also contribute
to the final binding pocket characteristics. [57] Thus, mutations which impinge upon subunitsubunit interactions can abolish or decrease proteolytic activity, interfere with autocatalytic
processing of the beta subunits, or destabilize the fully assembled proteasome. [57, 58, 61, 66]
The core particle itself is autoinhibited by the alpha subunits, specifically their C-terminal tails,
which cap the ends of the barrel and can prevent substrate entry. [67] α3 has an especially
important role in this process, as its tail projects across the axis of symmetry, and this inhibition
is relieved by the binding of a regulatory particle or treatment with sodium dodecyl sulfate. [67,
68]

Additionally, hydrophobic peptides have been suggested to stimulate proteolysis by

opening a channel in these alpha ring tails. [69] Alpha rings are formed with the help of
dedicated chaperones Poc3/4 (Pba3/4) while proteasomes in general also require the assistance
of Poc1/2 and Ump1p for normal cooperative assembly. [65, 70-72]
D. Proteasome structure, assembly, and localization in mammals
To begin to understand the assembly of human proteasomes, researchers looked to mice for
detailed mechanistic answers. Since mouse ubiquitin-proteasome pathway proteins generally
have high homology with human proteins, and mice express both constitutive and
immunoproteasome subunits, they are a better model for the human proteasome assembly
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process than yeast. From mouse studies it was determined that proteasome assembly is an
irreversible process which requires continuous protein synthesis. [22, 73, 74] The first step in
proteasome assembly is the formation of an alpha ring. [74] Mouse proteasome assembly
chaperones-3 and -4 (mPAC3/4) are homologous to yeast Poc3/4; they assist in the formation of
alpha rings and remain as some of the beta subunits are added. [70] Beta subunits are added
directly to the alpha ring as unprocessed propeptides to form precursor complexes (13S-16S).
[73, 74] This is the step in which homologous subunit exchange may occur, as inducible
proteasome subunits replace constitutive ones; proteassemblin, a homologue of yeast Ump1p,
steps in at this point to help chaperone the assembly process. [22, 73, 75]
These 13-16S precursor complexes are lost as 20S proteasomes are formed, a process which
occurs in the cytoplasm and may continue with the association of a 19S regulatory cap to form a
26S proteasome. [73, 74] It is important to note that processed catalytic subunits are found only
in 20S proteasomes, as subunit processing and complete proteasome assembly are concurrent
processes, and it is only after cleavage of the propeptide sequence that beta catalytic subunits
are proteolytically active. [22, 73, 74] 11S and 19S caps are ATP-dependent enzymes which
facilitate the deubiqutination and entry of substrates into the 20S catalytic core. [73] The
amount of these caps is rate limiting, so association with 20S core particles is rapid and leaves
many 20S proteasomes without a cap. [73, 76] Fully assembled 26S proteasomes, containing a
20S core and a 19S cap, can thus begin efficiently degrading proteins.
In humans, the process of assembling proteasomes proceeds in a similar manner. Human
proteasomes are composed of two symmetrical halves, each holding a single copy of each alpha
and beta subunit in their assigned position within their ring. [77] A number of chaperones are
involved in this process. First, PAC1/2 form a heterodimer to interact with α5 and α7, assisting
in the formation of an alpha ring. [78] The human analogue of yeast Ump1p and mouse
proteassemblin (95% identity), POMP (PrOteasome Maturation Protein), interacts with the ER
membrane and the alpha ring. [75, 79, 80] The levels of POMP mRNA increase upon treatment
with interferon-γ, likely resulting in increased protein levels which assist with more rapid
proteasome assembly. [79] POMP and the PAC3/4 dimer (homologues of yeast Poc3/4) then
assist in the recruitment of beta subunits onto the alpha ring. [70, 80] Unlike in yeast, human
proteasome propeptides are not essential for the correct positioning of subunits within the core
particle. [81] However, the β5 propeptide directs proteasome assembly to encourage the
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cooperative assembly of constitutive proteasomes and immunoproteasomes, rather than
intermediate proteasomes. [79, 82] Additionally, having a propeptide, even one of another
subunit, is important for the incorporation of the β5 and β5i subunits, which are the rate limiting
step of proteasome assembly. [82]
A knockdown experiment undertaken using siRNA in human embryonic kidney cells suggests
that beta subunit assembly begins with β2 binding to an alpha ring associated with POMP, which
requires the β2 propeptide and C-terminal tail. [83] This is followed by the addition of β3, which
is coupled to the loss of PAC3. [83] The addition of β4 creates the 13S half proteasome, a
commonly seen assembly intermediate. [83] β5 is then added and, assuming its propeptide is
present, β6 incorporates. [83] Apparently, β1 can incorporate at any time after β2/3, but its
incorporation is a prerequisite for the addition of β7. [83] Additionally, there is an interesting
correlation between β1i and β2i incorporation, with some studies suggesting β1i enhances β2i
incorporation, others suggesting the opposite, and some which postulate that the effect is celltype dependent. [35, 84, 85] Finally, when β7 is added to the ring, which requires the β7 Cterminal tail, the 16S half proteasome is formed. [83] β1 and β1i lose their propeptides while in
16S complexes; however, subunit processing and proteolytic activation do not coincide, as the
processing that occurs in 16S complexes is insufficient to provide proteolytic activity, and may
require additional factors. [74, 86]
This propeptide processing is a two-step autocatalytic process, requiring the Gly-1/Thr1
consensus motif and Lys33. [81, 86, 87] A key piece of evidence supporting this two-step
hypothesis is that the β1i mutant, where Ala1 is encoded in place of Thr1, results in an Nterminal extension of nine to ten amino acids resulting from cleavage between Gly-11/Ser-10 or
Ser-10/Phe-9, but does not affect subunit incorporation or complex assembly. [25, 81] A similar
result was seen with the same mutation in β2i. [39]
Finally, the tail of β7, along with POMP, assists in dimerizing the 16S proteasome halves. [80, 83]
This process can be disrupted by proteasome inhibitor subunit 31 (PI31), which decreases the
ability of 16S immunoproteasome to dimerize, although the mechanism for this inhibition is not
yet clear. [88] POMP then serves as one of the first substrates of the new, catalytically active
20S proteasome. [80]
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While many of the initial studies of constitutive and inducible subunits suggested cooperative
incorporation of all three beta catalytic subunits, other studies contradict these findings. [22, 24,
35, 36, 38, 44] In support of the cooperative hypothesis, a study found that treatment with
interferon-γ works quickly to reorganize proteasome types, decreasing the number of 20S cores
associated with 19S caps and increasing the number of immunoproteasomes, usually within 24
hours. [89] One of the first studies to contradict this hypothesis and suggest the existence of
intermediate proteasomes was a study done in mouse macrophages that found β5i to exist in
β1i-containing proteasomes as well as in proteasomes depleted of β1i. [28] Another group later
hypothesized the existence of eight possible half (16S) proteasomes if all catalytic beta subunits
can incorporate independently, which increases to 36 proteasome types if the composition of
the two beta rings are independent. [34] This suggests a high level of variability in proteasomes,
especially if each intermediate proteasome has different functions or expression levels.
Additionally, an increasing level of complexity is present when considering that the 20S cores
may associate with regulatory caps. These 19S and 11S caps assemble to form proteasomes
containing one, two, both, or no caps. [90] β1i and β5i are found both with and without caps,
although more are seen without. [76]
Studies in rats suggest that at least some of these intermediate proteasome cores exist in vivo,
as six subtypes of proteasomes were identified from rat muscle. [91] While the most abundant
type appeared to be constitutive proteasomes, a significant amount was of the intermediate
type (β1, β2, β5i and β1/β1i, β2, β5i), and a few were immunoproteasomes. [91] When the
authors examined rat spleen, the immunoproteasome type was most prevalent, with some
intermediate proteasomes as well (β1, β2i, β5i and β1/β1i, β2i, β5i). [91] Later work suggested
the presence of intermediate proteasomes in multiple myeloma (MM), plasmocytoid
lymphoma, T-cell lymphoma, non-Hodgkin’s lymphoma (NHL), colon adenocarcinoma, and lung
adenocarcinoma based on quantitation from enzyme-linked immunosorbent assays (ELISA). [92]
Since then, two major intermediate human proteasome subtypes (β1, β2, β5i and β1i, β2, and
β5i) have been identified as responsible for the generation of certain clinically-relevant tumor
antigens. [93] These subtypes are one-third to one-half of the proteasomes found in human
liver, colon, small intestine, kidney, dendritic cells, and tumor cells. [93]
These studies seem to also support the hypothesis that the composition of the two beta rings
which assemble to form 20S proteasomes are independent; both β1 and β1i are found in some
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subtypes, which was suggested previously in transfected human cells. [53] Additional work in
pancreatic cancer cell lines demonstrated high variability of β1i and β2i expression between cell
lines, suggesting the proteasome likely forms distinct subtypes in each cell line. [94] Perhaps
most significantly, the activity of each subtype against fluorogenic peptide substrates varied
considerably, and thus proteasome characteristics of tissues are an average of the activities of
the subtypes found in each tissue, even though each type of proteasome may have unique
activities and/or functions in vivo. [91]
Conclusive evidence for a different kind of intermediate proteasome came in 2007 with the
discovery of the thymoproteasome. A thymoproteasome contains β1i, β2i, and β5t, a novel
subunit located adjacent to the β5 gene and found exclusively in cortical thymic epithelial cells.
[95, 96] β5t has greatly reduced CT-L activity, likely due to its hydrophilic S1 pocket, allowing it
to produce the peptides necessary for the positive selection of major and diverse MHC class Irestricted CD8+ T cells. [95, 96] Studies in knockout mice demonstrated the non-lethality of β5t
knockouts, but also showed a severely defective response to allogeneic and viral antigens,
resulting in lethal influenza infection. [96]
When later studies confirmed the existence of proteasomes containing both constitutive and
immunoproteasome catalytic beta subunits, they were found in the cytoplasm, nucleoplasm,
and microsomes of HeLa cells. [97, 98] As Marian Orlowski and colleagues noted in 1999, “There
is a tendency to assume that substrate binding properties, and therefore specificity of a pair of
identical catalytically active subunits, are the same.” [99] As the active sites of the proteasome
are actually formed by pairs of neighboring beta subunits, one can postulate that intermediate
proteasomes may have some effect on the function of identical beta catalytic subunits. [77]
One could also postulate that proteasomal cellular localization may be unique between types or
have functional consequences.
Proteasomes are generally found throughout mammalian cells, diffusing rapidly throughout the
cytoplasm and nucleus, but are absent from the perinuclear region (i.e.: nuclear envelope) and
nucleoli. [53, 100] Studies in rodents showed that proteasomes are found in nuclear, cytosolic,
and microsomal fractions but not always at the same levels. [73, 101]

For example,

proteasomes levels in rat liver are ten-fold higher in the cytosol than nuclei and six- to sevenfold higher in the cytosol than the microsomes. [101] Additionally, membrane-bound
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proteasome have been localized to the exterior membranes of the smooth endoplasmic
reticulum, cis-Golgi, and mitochondria. [101, 102]
Interestingly, proteasomes are only able to diffuse slowly and unidirectionally from the
cytoplasm to the nucleus of interphase cells, although they can move about freely during mitosis
until the nuclear envelope is restored. [53] While the nuclear distribution of proteasomes is
species-specific and varies between higher and lower eukaryotes, human proteasomes are
found in speckles, nuclear bodies, nucleoplasmic foci, and diffusely throughout the nucleoplasm
in interphase human epithelial cells. [103] These nuclear proteasomes have significant
proteolytic activity as they seem to co-localize with and degrade substrate proteins in specific
subnuclear foci, such as splicing speckles and PML bodies. [100, 103, 104]
E. Constitutive and immunoproteasome functions
The proteasome is a proteolytic enzyme complex consisting of Ntn-hydrolases and noncatalytic
subunits, yet the question of function remains partially unanswered. Generally speaking, the
main function of the proteasome is the degradation of proteins. Its function is both this simple
and much more complex. Protein degradation is a method by which cells regulate protein
function, perhaps best demonstrated by the proteasome-dependency of cell cycle progression.
Cellular responses to oxidative and other kinds of stress conditions rely on proteasomes, such
that tissues with higher proteasome activity (such as the liver) cope better with stress than
those with lower proteasome activity (such as the brain). [105] Oxidized proteins can be
degraded without ubiquitin conjugation by any fully assembled form of the proteasome. [106]
Likewise, in cells with compromised ubiquitin-conjugating activity, proteasomes preferentially
degrade oxidized proteins at nearly normal rates. [106] It is important to note that proteasome
complexes are stable during the degradative process. [107]
The overall composition of the proteasome complex affects the activity of the proteasome, as
do levels of detergents, ATP, and cytokines, as well as the substrate being degraded. [30, 90, 99,
108, 109] Generally, 26S proteasomes degrade proteins into peptide fragments containing 3-22
amino acids (mean=8), fitting a log normal distribution; the size of these peptides is similar
between 26S and 20S rabbit muscle proteasomes as well as T. acidophilum proteasomes. [40,
110] However, the 26S and 20S proteasomes from rabbit muscle cleave the same peptides
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differently, and inhibition of multiple catalytic beta subunits is necessary to substantially
decrease protein proteolysis. [40, 111]
Proteasomes are likewise a major player in the production of peptides for antigen presentation.
While the proteasome determines both the N- and C-termini of peptides during cleavage, it is
the C-terminus which is more important for antigen presentation. [29, 112]

Prior to

presentation, however, these peptides may undergo additional processing to produce an
antigen of the correct size and sequence. The proteasome is sufficient to generate the correct
C-termini of epitopes, but another protease is responsible for generating the correct Nterminus. [29, 112]

As one might expect, proteasome inhibition can modulate antigen

presentation when the inhibition is partial and selective, or block it completely at high levels.
[13, 113]
Additional unorthodox roles for the proteasome have been elucidated in recent years.
Proteasomes co-precipitate with eukaryotic initiation factor 3 subunits, ribosomal proteins, and
glutamyl-tRNA synthetase in a supercomplex known as the translasome. [114] Proteasomes
also influence the transcriptional machinery as well as histone methyltransferases. [115] More
interestingly, unequal partitioning of proteasomes between daughter cells during metaphase in
T lymphocytes is responsible for the unequal distribution of proteins into daughter cells,
promoting unique differentiation events in each. [116] Increased expression of the proteasome
subunit β5 has been shown to enhance resistance to oxidative stress and increase the number
of doublings prior to senescence. [38] Perhaps it is not surprising that increased expression of
26S proteasome genes is correlated with tumor progression and metastasis, accurately
predicting clinical outcomes of breast cancer patients. [117]
The functions of immunoproteasomes, on the other hand, are less well defined.
Immunoproteasomes are also protective against oxidative stress and degrade oxidized proteins
efficiently. [118] In a human lymphoblastoid cell line, mutating β5i, and thereby inhibiting its CTL activity, has a significant effect on the growth rate of cells, which suggests this activity is
required for survival. [79] In general, immunoproteasomes seem to degrade substrates more
rapidly than constitutive proteasomes. [89]
26S immunoproteasomes produce peptides of 3-22 amino acids (mean=7-8) fitting a log normal
distribution.

[110]

Compared

to

constitutive
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proteasomes

(from

rabbit

muscle),

immunoproteasomes (from rabbit spleen) cleave a hydrophobic substrate [Z-GGL-AMC] 50%
faster, a basic substrate [Boc-LRR-AMC] 100% faster, and an acidic substrate [AcYVAD-AMC] at
20% of the rate of proteasomes. [110] This loss of acidic proteasome cleavage can be most
directly linked to the replacement of β1 by β1i. [21, 24, 25] Homology studies suggest that the
altered amino acid composition of the S1 pocket of β1i makes it more apolar and constricted
which should reduce the C-L activity and promote the CT-L activity of this subunit. [57]
Some more exotic roles for immunoproteasomes have been discovered as well. They have a
role in proper retinal function in mice, as retinal function is disturbed in β2i/β5i knockout mice.
[119] β1i is involved in human trophoblast invasion, the process by which a human embryo
implants and interacts with the maternal uterus. [120] Proteasomes containing β1i are also
recruited by steroid receptor coactivators and enhance estrogen receptor-mediated
transcription, both at the initiation and elongation steps. [121]
When it comes to antigen presentation, immunoproteasomes have varying levels of efficacy in
producing the correct antigenic peptide. It is well understood that the importance of any
particular catalytic subunit for antigen presentation is epitope dependent. [25, 85, 109-111, 122,
123]

Dendritic cells, a set of antigen presenting cells which constitutively express the

immunoproteasome, are incapable of producing antigenic peptides generated by the
constitutive proteasome, a finding that has implications for vaccine development. [124] The
products of insulin-like growth factor 1 cleavage vary significantly when comparing proteasomes
to immunoproteasomes of rabbits. [110] An analysis of ten antigens from melanoma shows that
four were presented more efficiently after immunoproteasome induction while six were
presented less efficiently. [124] For example, the immunodominant epitope of the Ova protein
is produced by immunoproteasome cleavage of Ova 11% of the time, but it is only produced 6%
of the time when Ova is cleaved by the constitutive proteasomes. [110]

Likewise,

overexpression of β1i, β2i, and β5i greatly improved the presentation of an immunodominant
lymphocytic choriomeningitis virus T cell epitope, although neither β1i or β5i was required for
clearance of this viral infection in mice. [122, 123] β5i, however, is essential for the survival of
mice after infection with Toxoplasma gondii. [125] Addition of catalytically inactive β1i (T21A)
reduces the processing and production of some antigenic peptides, but may enhance that of
others. [25] Similarly, the production of these antigenic peptides, but not other parts of the
peptide presentation process, can be blocked by inhibiting the immuno/proteasome. [30]
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Bioinformatics analysis shows that immunoproteasomes cleavage is more amino acid specific
than constitutive proteasome cleavage, as immunoproteasomes cleave after fewer amino acids
residues. [126]

Interestingly, the use of the highly abundant amino acid leucine as a

degradation signal allows the immunoproteasome to degrade proteins with a similar efficiency
when compared to constitutive proteasomes. [126] The increase in CT-L activity found in
immunoproteasomes allows for the generation of significantly more potential MHC class I
ligands than constitutive proteasomes; however, these changes in proteasome activities do
destroy some antigenic peptides. [109, 124, 126]
Interferon-γ also plays a major role in the efficient production of antigens. It stimulates the
production of leucine aminopeptidase (LAP) and endoplasmic reticulum associated protein 1
(ERAP1), proteins which trim the N-termini of peptides. [29, 127] ERAP1 trims these N-termini
sequentially, but not processively, and cannot trim peptides shorter than 8 amino acids. [127,
128] Additionally, interferon-γ induces the expression of the subunits of the 11S regulatory
particle, which enhance antigen presentation independently of any changes to the beta catalytic
subunits. [129]
A way to begin to examine the possible function of immunoproteasomes and their beta catalytic
subunits is to knock out these subunits in mice and explore the phenotypic results. β1i, β2i, and
β5i knockout mice have been generated and found to be without gross physical abnormalities.
[44, 47, 130] β5i knockout mice were the first to be reported; they show reduced MHC class I
expression on cell surfaces, present some peptides less efficiently, but have normal numbers of
T and B cells. [44, 131] The effect of β5i on MHC class I expression is dominant, as seen in the
case where β5i knockout mice die from T. gondii infections which are not lethal to wild type
mice. [125, 131] While loss of β5i is deleterious to the infectious response, it seems to be
beneficial in a mouse model of colitis, a disease characterized by intestinal inflammation. β5i
knockout mice recover more quickly from dextran sulphate sodium-induced colitis and have less
severe disease, likely due a reduction in the proinflammatory T cell and mucosal immune
responses in the colon of β5i knockout mice. [132]
On the other hand, β1i knockout mice were reported to have reduced levels, but not altered
ratios, of CD8+ T lymphocytes in the blood, spleen, and thymus. [47, 122, 131] Similarly, their
ability to present antigens and activate T cells in response to infection was lessened. [47] This
may be due to the fact that loss of β1i has been shown to alter the overall composition of the
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proteasome, although β5i incorporation is not significantly affected. [47] These mice are more
susceptible to T. gondii infection than wild type mice, but less so than β5i knockout mice. [125]
β1i knockout mice also have smaller hearts and lower heart rates than wild type mice. [49, 133]
Further studies of the β1i knockout mice showed that their ambulation and cognitive function
were the same as control mice of the same background, but they had a higher body weight and
degree of motor function. [49, 133, 134] One study suggests that the increased motor function
observed in patients with Parkinson’s and Huntington’s disease may relate to changes in
proteasome subunit expression in the brains of these patients. [134]
Proteasome activity in the spleen and liver, but not the muscle and brain, was altered in β1i
knockout mice. [47] They thus assemble mixed proteasomes in a tissue specific manner, which
likely compromises antiviral antibody responses. [135] Moreover, levels of β5i and β2i were
significantly reduced in β1i knockout hearts, resulting in lower proteasome activities worsened
by ischemic preconditioning. [133] This lack of cardioprotection in knockout animals can be
traced to their inability to inactivate phosphatase and tensin homolog (PTEN) by degradation in
the heart. [49, 133] The cardiomyopathy seen in the knockout mice is similar to that observed
in type 2 diabetic hearts, suggesting immunoproteasome subunit expression may be responsive
to blood insulin levels. [49] Interestingly, female β1i knockout mice develop spontaneous
uterine neoplasms as they age, while β1i/p53 double knockout mice have a small but significant
reduction in survival. [136, 137]
β2i knockout mice have fewer CD8+ splenocytes than wild type mice and show a reduction of
cytotoxic T lymphocyte response to certain epitopes in response to infection with lymphocytic
choriomeningitis virus. [130] While β2i knockout mice incorporate β5i efficiently, β1i
incorporation is reduced, suggesting cooperative assembly of these two subunits. [130] Double
knockout mice of β2i and β5i were also created and found to possess fewer CD8+ T cells in the
spleen. [131]

After subjecting these mice to whole body irradiation and bone marrow

transplantation, multiorgan autoimmunity develops with the lack of immunoproteasome
subunits in the target tissues in a causative role. [138]
F. The ubiquitin-proteasome pathway and immunoproteasomes in disease
As one might imagine from their important role in normal cellular functions, the ubiquitinproteasome pathway and its constituents play distinct and important roles in a variety of
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disease states. Pure numbers would suggest these enzymes are important, even excluding their
function as regulators of cellular proteins.

Current estimates show eight E1 enzymes,

approximately 40 E2s, and almost 100 DUBs in five families. [139] A single subtype of E3 ligases
alone exceeds the total number of kinases in cells. [139] As the majority of cellular proteins
proceed through this pathway prior to degradation, the proteasomes control a number of
important proteins implicated in disease.

Immunoproteasomes specifically have been

implicated in cancers as well as autoimmune, inflammatory, neurological, and infectious
diseases. Unfortunately, some of these studies rely on mRNA upregulation to suggest the
protein is important to the disease process, though studies have clearly shown that upregulation
of proteasome subunit mRNA does not always translate to increased protein expression. [45,
46]
Perhaps the most controversial link between immunoproteasomes and autoimmune disease
came from Faustman’s group, who suggested that β1i plays a role in the reduction of NF-κB
activation in a mouse model of diabetes (NOD), a link strongly disputed by the groups of Ploegh
and Monoco. [140-143] Resolution of this issue awaits a truly selective β1i inhibitor and a group
interested in wading into such rough waters. Other, better accepted links between autoimmune
diseases and immunoproteasomes are found in the more recent literature.

Circulating

proteasomes are detected at significantly higher levels in patients with active systemic
autoimmune diseases (autoimmune myositis, systemic lupus erythematosus (SLE), primary
Sjögren’s syndrome, rheumatoid arthritis (RA), and autoimmune hepatitis) compared to healthy
controls and are thought to correlate with other markers of disease severity/activity, possibly
representing the extent of systemic cellular damage. [144] Two patients were shown to have
β5i present in their circulating proteasome samples. [144] Another study examining primary
Sjögren’s syndrome found upregulation of β1i, β2i, and an 11S subunit (PA28α) mRNA levels,
but downregulation of the β1i protein when compared to normal controls. [45] Interestingly,
the other autoimmune patient tissues examined in this study had increased β1i subunit
expression compared to normal controls. [45] Expression of β1i has also been correlated with
Hashimoto thyroiditis and psoriasis in patients. [145, 146] β5i expression is correlated with
Hashimoto thyroiditis and type I diabetes. [49, 138, 145]
Due to the role of immunoproteasomes in antigen presentation, research into the effects of the
immune system and infection on proteasome composition is expanding. In the area of vaccine

19

development, researchers are finding that in those proteins for which the immunodominant
antigen(s) are not produced by the immunoproteasome (the major proteasome subtype in
antigen presenting cells), vaccines should contain the immunodominant peptide rather than the
whole protein. [124] A number of viral infections utilize this weakness of the immune system
and hijack the cellular processes by which immunoproteasomes are produced to avoid detection
by the immune system. [147] Specifically, while infection of mice with the lymphocytic
choriomeningitis virus in the brain leads to upregulation of immunoproteasome catalytic
subunit mRNA, few active and assembled proteasomes are found there, likely due to posttranslational regulatory mechanisms. [46] Mouse cytomegalovirus actually makes a protein
(M27) which inhibits Stat2 and disrupts interferon-γ signaling, leading to the blockage of
immunoproteasome subunit transcription. [147] Human cytomegalovirus can also block the
production of immunoproteasome subunits. [147] Interestingly, one study suggests that type I
interferons (alpha and beta, predominately) may actually be more important for the
upregulation of immunoproteasome subunits in infections than the classically important
interferon-γ. [148] Much still remains to be understood about the role of immunoproteasomes,
constitutive proteasomes, and intermediate proteasomes in the immune response to infection.
Neurological disorders are perhaps the most surprising pathology for which immunoproteasome
expression has been indicated, considering the immunoprivileged status of the brain. The link
between the brain and immunoproteasome subunit expression was first suggested in studies
with knockout mice, and later examined in other rodents. [134] In a conditional mouse model of
Huntington’s disease, β1i and β5i but not β2i were upregulated in the cortex and striatum after
significant neuropathy had occurred. [149] Further examination found β1i upregulation in all
cortical neurons displaying the ultrastructural features of degeneration. [149]

A more

mechanistic study in a rat model of amyotrophic lateral sclerosis (ALS) showed that
immunoproteasome upregulation was a compensatory response to the disease, such that
blocking immunoproteasome induction is quite deleterious in this model. [150] In animal
models of experimental autoimmune encephalomyelitis (EAE), a model for multiple sclerosis
(MS), upregulation of β1i, β2i, β2, and β5 was seen. [151] Unlike the ALS model, however,
treatment with a proteasome inhibitor alone, or in combination with lysosomal inhibition,
seems to be a potential therapeutic strategy. [151]
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When examining patients with neurodegenerative conditions, links have been found between
immunoproteasome subunit expression and disease pathology. For instance, in grade four
Huntington’s disease patients, β1i and β5i expression increased in the cortex and striatum when
compared to age-matched controls. [149] Additionally, β1i expression in the hippocampus and
cerebellum, specifically in the neurons and astrocytes, was higher in patients with Alzheimer's
disease compared to non-demented elderly. [152] The young show no such expression of β1i in
these parts of the brain. [152] Another study looking at risk factors for MS in Italians found
females with a certain allele combined with a β1i polymorphism have a lower risk of developing
MS, possibly due to fewer autoreactive T cells. [153] This lends support to further investigations
of the role of immunoproteasomes in neurological disorders.
Another group of pathologies which upregulate immunoproteasomes are inflammatory
diseases. In general, immunoproteasomes play a role in the cellular damage response to
stresses such as interferons, lipopolysaccharide, arsenic trioxide, nitric oxide, and heat by
clearing the cells of damaged proteins. [89] Immunoproteasomes actually clear oxidatively and
otherwise damaged proteins more quickly than constitutive proteasomes. [89] Thus, an
expected effect of diseases associated with inflammatory cytokines is immunoproteasome
upregulation, although this may not always be beneficial. In inflammatory bowel disease (IBD),
immunohistochemistry detected increased β1i expression in diseased and histologically normal
tissues from IBD patients compared to healthy control patients. [154] The correlation between
β1i expression and histological grade and/or intestinal pathology of these patients was highly
significant. [154] Similar results were found in the livers of patients with chronic alcoholic
hepatitis and hepatic cirrhosis. In these patients, β1i and β5i immunohistochemical staining was
highly significantly increased overall, as well as in the nucleus, when compared to normal
tissues. [51] In an inducible model of ulcerative colitis, a type of IBD, β5i knockout mice recover
more quickly and have less severe disease than control mice, possibly due to a reduction in the
proinflammatory response of the mucosal immune cells. [132] Inhibition of the proteasome
using small molecule drugs gave a similar or better effect than β5i knockout, although high
doses of proteasome inhibitors produced severe, drug-mediated side effects. [132]
Some diseases are associated with changes in the amino acid sequence of proteasome catalytic
beta subunits rather than their expression levels. For instance, hypersensitivity pneumonitis, an
inflammation of the lung due to the inhalation of organic particles by a susceptible patient, is
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very significantly associated with β5i and β1i polymorphisms. [155] More recently, single
polymorphisms in β5i were found in two different inflammatory diseases: JMP, an autosomalrecessive syndrome presenting with joint contractures, muscle atrophy, microcytic anemia, and
panniculitis-induced childhood-onset lipodystrophy and Nakajo-Nishimura/JASL, characterized
by joint contractures, muscle atrophy, fever, rash, and loss of adipose tissues. [156-158] These
mutations have been shown to disrupt the tertiary structure of the β5i protein, reducing both its
incorporation into proteasomes and its catalytic activity. [156-158] As more groups begin to
explore this portion of the proteome, additional correlations will likely be discovered.
Ubiquitin-proteasome pathway dysfunction is observed in most, if not all, cancers. [159] As the
components of this pathway are so numerous, it is unlikely that there will be any one target
which will be generally therapeutic. However, proteasomes may serve as an indicator of the
severity or activity of diseases, such as autoimmune myositis, SLE, primary Sjögren’s syndrome,
RA, autoimmune hepatitis, and cancers. [144, 160] In case studies, researchers were able to
correlate the disease process with the levels of circulating proteasomes, which may represent
the extent of systemic cellular damage. [144, 160]
Circulating proteasome levels are also important in the case of monoclonal gammopathy of
undetermined significance (MGUS), a disease that is best described as a milder version of MM.
Specifically, the levels of circulating proteasomes are higher in MGUS patients compared to
healthy controls, and are higher in MM patients than MGUS patients. [160] Additionally,
increased concentration of circulating proteasomes correlates with advanced MM and is an
independent prognostic factor for MM. [160] As proteasome inhibitors are currently indicated
primarily for MM, this finding represents an interesting and novel way to track progression of
the disease and also suggests the importance of the proteasome in the disease process.
As Hanahan and Weinberg note in, “Hallmarks of cancer: the next generation” an update of
their seminal review article from 2000, two of the emerging hallmarks of cancer are tumorpromoting inflammation and evading immune destruction. [161, 162] The regulation of the
immunoproteasome can be linked to both of these hallmarks. Immunoproteasome catalytic
subunit expression is often important for cellular responses to inflammation, due to molecules
such as interferons, tumor necrosis factor-α, nitric oxide, and lipopolysaccharide promoting
immunoproteasome formation in cells. [25, 85, 89, 109-111, 122, 123, 148, 163-165] Quite a few
studies have examined the role of immunoproteasomes in the antigen generation process of
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cancers. The vast majority of studies thus far indicate a correlation between downregulation of
the components of the antigen processing pathway and disease progression. It is postulated
that loss of these proteins may assist malignant cells in avoiding immunosurveillance. [166]
Dendritic cells are antigen presenting cells that play a major role in immunosurveillance by
activating T cells using antigens recovered from tumor cells. These activated T cells can then
destroy any cancerous cells which express this antigen. A recent study suggests that reducing
the immunoproteasome levels in dendritic cells may induce an antitumor response to cancers
containing mainly constitutive proteasomes. [167] Additionally, the expression of β1i and β5i is
correlated with the presence of tumor-infiltrating lymphocytes and spontaneous regression in
melanomas. [168]
The next pressing question is how cancer cells may be able to prevent the expression of
immunoproteasome beta catalytic subunits.

A study in melanoma cells utilized histone

deacetylase (HDAC) inhibitors to demonstrate that downregulation of these proteins (including
β1i and β5i) may occur epigenetically, although changes in mRNA but not protein levels were
examined. [169] Additional support for this epigenetic downregulation hypothesis comes from
another study showing interferon-γ is capable of inducing expression of β1i, β5i, TAP1, and TAP2
in small cell lung cancer, Whilm’s tumors, prostate cancer cell lines, and a neuroblastoma which
normally show low to no expression of these proteins. [43] The downregulation of these same
four proteins is also seen in the progression of low grade to high grade melanoma as well as in
two acute myeloid leukemia patients followed from diagnosis to relapse. [166, 170]
Coordinated downregulation of at least seven of these antigen processing machinery
components was found in 41% of prostate cancer patients with early recurrence, but only 24%
of patients without recurrence. [171]
More specifically, immunoproteasome catalytic subunit expression levels vary in a number of
malignancies. β1i, β2i, and β5i expression was significantly lower in high-stage urothelial
carcinomas than low-stage ones. [172] In the progression of MGUS to MM, β1i, β2i, and β1
levels decrease, suggesting changes in expression may be predictive of progression from MGUS
to MM. [173] The expression of β1i and β5i was reduced or lost in 45% and 48% of esophageal
squamous cell carcinomas, respectively, and it was strongly correlated with tumor grade and
lymph node status. [174] In prostate cancer, β1i and β5i expression are lower, as detected by
immunohistochemistry, compared to normal prostate tissue. [171] β1i and β5i are also
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expressed in Hürthle cell adenomas and carcinomas, but with great interpatient and intrapatient
variability. [145] Breast cancer patients with high expression of β5i as detected by microarray
have significantly shorter survival time. [175] Additionally, knockdown of β5i expression in a
resistant breast cancer cell line resensitized the cells to doxorubicin. [175] In the brain,
astrocytomas express less β1i than astrocytes, and this downregulation was correlated with
grade of the malignancy. [176]
Interestingly, there are a few reports which suggest β1i expression is important for cancer
growth and metastasis. In the case of hydatidiform moles, a nonviable but fertilized egg
implanted into the uterus, β1i overexpression may play a role in the highly metastatic
phenotype sometimes seen in these abnormal growths, which can develop into a carcinoma.
[120] Additionally, β1i has been shown to be important for the formation of oncocytes,
hypothyroidism, and interferon-γ-induced thyroid growth defects. [145] While these studies
seem to complicate the relationship between immunoproteasomes and cancer cell growth,
interferon-γ pretreatment was shown to enhance the sensitivity of half of the solid tumor cell
lines tested to a proteasome inhibitor drug. [177] This strongly suggests that cells which express
immunoproteasomes are sensitive to their inhibition, and thus, proteasome inhibitors may be a
viable therapeutic option for certain solid malignancies.
G. The development of proteasome inhibitors
As mentioned above, the first proteasome inhibitors were the peptide aldehydes Z-LLF-CHO, AcLLnL-CHO, and Ac-LLM-CHO. [12]

Through their library-based approach, M. Orlowski and

colleagues found that aromatic residues in the P1 position increase the affinity of the inhibitor
for the proteasome’s CT-L activity. [12] Later studies showed that peptide aldehydes with
leucine as well as phenylalanine in the P1 position were effective inhibitors of bovine pituitary
proteasome’s CT-L activity. [99] Additionally, the P2 position is often found to be extremely
accommodating, as it faces away from the catalytic subunit in yeast proteasomes. [57] Ac-LLnLCHO was used in crystal studies of the yeast proteasome and found to bind to β1, β2, and β5 at
the Thr1 side chain hydroxyl, likely as a hemiacetal. [57] Further medicinal chemistry efforts
yielded Carbobenzoxyl-LLL (MG132) and carbobenzoxyl-LLnV (MG115), which were found to
block the degradation of short-lived proteins in yeast (Figure 1.2.A). [178] Later studies with
aldehyde inhibitors of specific activities in proteasomes purified from rabbit muscle showed that
the CT-L activity is responsible for 11-50%, the C-L activity is responsible for 12-22%, and the T-L
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activity is responsible for 3-35% of the degradation of model proteins. [111] Thus, to block more
than 50% of the proteasome’s activity requires the inhibition of multiple types of catalytic sites.
[111] Perhaps most notably, Goldberg and colleagues remark that, “…the rates of proteolysis
measured upon inactivation of one site do not simply reflect the contribution of that site but
also the capacity of the residual sites to catalyze the degradation of the specific substrate.”
[111] While the further development of the aldehyde class of proteasome inhibitors has been
limited by concerns regarding cross reactivity with cysteine and serine proteases, they have
been utilized in a number of the important studies of the proteasome and assisted in the
development of selective proteasome inhibitors.
A natural product, lactacystin, was discovered in 1991 to induce the differentiation of
neuroblastoma cells (Figure 1.2.B). [179, 180] Later work by the Stuart Schreiber and EJ Cory
labs found that lactacystin bound to the catalytic threonine of proteasome catalytic subunits,
irreversibly inhibiting its T-L and CT-L activities, and its effect on neurite outgrowth was directly
correlated to the degree of proteasome inhibition. [181] While lactacystin prefers the CT-L
activity, it can inhibit all three main proteasome activities and modify all six beta catalytic
subunits of human proteasomes while not binding reproducibly to other proteins in
lymphoblastoid cell lines. [30] Later work showed that the β-lactone of lactacystin was capable
of blocking the degradation of short lived proteins in yeast, similar to the effects of MG132 and
MG115. [178] Groll and colleagues’ yeast crystal structure demonstrated that lactacystin bound
to the β5 subunit, where it acetylates the side chain hydroxyl of Thr1 as a result of the β-lactone
ring opening. [57] Additional work that same year showed that lactacystin is a more specific
inhibitor of the proteasome than the peptide aldehydes and that it also inhibits interferon-γinducible proteasomes. [30] Interestingly, the localization of proteasomes is not affected by
proteasome inhibitors, but after 24 hours of treatment, proteasome inhibitors induce a
significant increase in proteasomal staining intensity. [100, 103] Later work suggested that the
β-lactone pharmacophore also binds to other proteases. [182-184] This, combined with the
highly complex synthesis of β-lactones, discouraged further medicinal chemistry efforts. Still
lactacystin remains a popular tool for cell and molecular biologists even today.
Another early class of proteasome inhibitors was the vinyl sulfones.

The inhibitor N-

carboxybenzyl-leucil-leucil-leucil-vinyl-sulfone (Z-LLL-VS) covalently inhibits all three main
proteasome activities in purified proteasome as well as in cell lines, although it binds to other
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Figure 1.2: First generation proteasome inhibitors. The structures of some early proteasome
inhibitors are depicted. A. The peptide aldehydes MG115 and MG132. MG132 is still used today
as a general proteasome inhibitor. B. The natural product proteasome inhibitor lactacystin and
synthetic inhibitor Z-LLL-VS. C. Molecular probes of proteasome function.
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proteases as well (Figure 1.2.B). [56] This class of molecules has been important in studies to
understand the binding characteristics of substrates and inhibitors. For example, vinyl sulfone
tetrapeptides were used to elucidate the importance of the P4 position for directing binding
specificity to active sites, providing more subunit selective inhibitors. [185] In inhibitors with
tetrapeptide length or longer, there appears to be less sequence specificity for the catalytic
activities than is typically assumed based on the results from small peptide-based substrates and
inhibitors. [186] Vinyl sulfones also provided more general proteasome inhibitors, such as
adamantaneacetyl-(6-aminohexanoyl)3-(leucinyl)3-vinyl-(methyl)-sulfone (Ahx3L3VS), which binds
all six active sites and can be labeled with radioisotopes, biotin, or fluorescent groups (such as
MV-151) (Figure 1.2.C). [186] The popularity of vinyl sulfones is limited by their affinity for
cysteine proteases, against which they were originally developed, but vinyl sulfones are still
used today as molecular probes of proteasomes.
In 1998, dipeptidyl boronic acids were reported to be potent and selective proteasome
inhibitors. [187] Boronic ester inhibitors were initially developed to target serine proteases, but
boronic acids were shown to be highly selective for the proteasomes over other proteases. [187]
Interestingly, boronic acid proteasome inhibitors interact with the proteasome in a competitive
but slowly reversible manner. [188] These inhibitors were initially developed in hopes of
treating muscle-wasting diseases, but many doctors and biologists were fearful that inhibiting
the proteasome clinically would be extremely toxic. [189] The researchers at ProScript quickly
decided using these boronic acid proteasome inhibitors as chemotherapeutic agents would be
the best way to develop this drug class, as oncology doctors and patients are much more willing
to tolerate significant side effects if the drug is effective. [189] Millennium Pharmaceuticals
acquired ProScript in 1999 and brought the lead boronic acid proteasome inhibitor into clinical
trials in 2000.
In the meantime, a final class of natural product proteasome inhibitors, the epoxyketones, was
described in 1999. [190] Eponemycin was shown to bind β1i, β5i, and β5 as well as inhibiting
cancer cell growth by causing apoptosis (Figure 1.3.A). [190, 191] Epoxomicin, on the other
hand, was shown to bind β2, β2i, β5, and β5i (Figure 1.3.A). [190, 192] It inhibits primarily the
CT-L activity of bovine proteasomes at low nanomolar doses, but does not inhibit other
proteases such as trypsin, chymotrypsin, papain, calpain, and cathepsin B at concentrations up
to 50µM. [192] Crystal structure work was able to show that epoxyketones, epoxomicin
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Figure 1.3: Epoxyketone proteasome inhibitors and their mechanism of action.

A. The

structure of the natural product proteasome inhibitors eponemycin and epoxomicin, as well as
the synthetic analogues YU101 and YU102. B. At top, the pertinent portions of the epoxyketone
proteasome inhibitor and catalytic beta subunit are shown. The atoms in red will be part of the
morpholino ring. Activation of the threonine by a nucleophile (such as water) allows the
threonine to attack the ketone, opening the epoxide ring with simultaneous closure of the
morpholino ring.
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specifically, form a morpholino ring with Ntn-hydrolases, covalently inhibiting their catalytic
activity (Figure 1.3.B) [193]. Epoxomicin helped demonstrate the validity of partial and selective
in vivo proteasome inhibition as an approach to alter antigen presentation, although the effects
were epitope-dependent. [113] Medicinal chemistry efforts with epoxyketones led to the
development of YU101, a very potent and selective CT-L activity inhibitor with good antiinflammatory activity; further efforts provided YU102, a C-L selective inhibitor (at least 50-fold
more potent towards the C-L activity than CT-L activity) which did not inhibit protein
degradation as a single agent in bovine aortic endothelial cells (Figure 1.3.A). [194, 195] Later
medicinal chemistry efforts would be focused on increasing the specificity and potency of these
diverse classes of proteasome inhibitors.
H. Proteasome inhibitors as therapeutic agents
Proteasome inhibitors are now changing people’s lives in the oncology clinic. In 2000, the first
MM patient who received a proteasome inhibitor in a Phase I study, designed primarily to
evaluate safety, had a complete remission. [189] Due to such spectacular results as well as close
collaboration with the Food and Drug Administration (FDA) and patient groups, bortezomib
(MG341/PS-341/Velcade™) was approved in 2003, before the final Phase III trial was complete.
Bortezomib is a boronic acid pharmacophore-based proteasome inhibitor, originally approved
for relapsed or refractory multiple myeloma (Figure 1.4.A). At the end of 2006, bortezomib was
approved for use in mantle cell lymphoma patients who had received at least one prior therapy.
This indication was extended in 2008 to include all stages of multiple myeloma, allowing for the
use of bortezomib as a first line treatment. As of March 2010, over 160,000 patients have been
treated with bortezomib. [196]
Bortezomib works in multiple myeloma by inhibiting proteasomal proteolysis. In primary MM
cells, proteasome activity is inversely correlated to the apoptotic sensitivity of cells to
proteasome inhibitors. [197] Interestingly, when looking at MM cell lines, this does not hold
true. Altering the proteasome expression or proteasome workload of a cell lines changes its
sensitivity to proteasome inhibition. [197] When one compares sensitive to resistant cells lines,
sensitive cells express low levels of proteasomes and have higher levels of proteasomemediated turnover. [197] While many researchers use peripheral blood mononuclear cells
(PMBCs) as surrogate markers for proteasome inhibition in tumor cells, these results suggest
that PMBCs may not accurately recapitulate the proteasome inhibition seen in tumor cells. [198]
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Figure 1.4: Proteasome inhibitors (circa 2008). The structures of published proteasome
inhibitors are depicted. A. Boronic acid pharmacophore containing proteasome inhibitors. B.
Marizomib, the beta-lactone proteasome inhibitor. C. Epoxyketone proteasome inhibitors,
including our lead compound, UK-101.
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Mechanistically, bortezomib targets β5, β5i, β1, and β1i at clinically relevant concentrations; as
one might expect, the T-L activity is often increased after bortezomib treatment, as it tries to
make up for loss of the other proteolytic activities. [198, 199] Treatment activates caspase-8and caspase-9-dependent apoptosis. [199]
Due to the resounding success of bortezomib in MM patients, Millennium quickly began trials of
bortezomib alone or in combination for other indications, mostly cancers. These studies have
indicated that proteasome inhibitors in combination therapy will require optimization of
treatment sequence and interval in addition to dose. [200] Preclinical evidence in other bloodborne cancers suggests that bortezomib also causes caspase-4-mediated (ER stress-induced)
apoptosis. [201] Likewise, neoplastic B cell lines which overexpress β1i and β2 were most
sensitive to bortezomib, while treatment of solid tumor cell lines with interferon-γ enhanced
their sensitivity to bortezomib. [177] There have been 561 clinical trials of bortezomib, Phase IIV, and 214 are currently open. [202]
While the efficacy of bortezomib was well-established in hematological malignancies, its
potential as a monotherapy in solid tumors, especially those with limited therapeutic options
and low survival rates, needed to be investigated. Preclinical studies in non-small cell lung
cancer (NSCLC) examined mechanistically which characteristics lead to sensitivity to bortezomib
treatment. They found that, to cause apoptosis, bortezomib must do two things: inhibit
proteasomal proteolysis and overcome the cell’s intrinsic resistance to apoptosis. [203] Using
apoptosis as an end-point has been suggested to say as much about a cell’s lack of general
resistance mechanisms, such as efflux pumps or proteasome overexpression, as it does about its
actual sensitivity to loss of proteasome function. [203] As Mortenson and colleagues suggest,
“Therefore, the effect of bortezomib may not be sensitization of cancer cells to the apoptotic
effect of chemotherapy, but may be modulating the cellular response to the chemotherapeutics
and thereby accentuating cell death.” [200] A study in ovarian cancer showed that cancerous
cells have increased levels of proteasome expression and polyubiquitinated proteins compared
to immortalized epithelial ovarian tissues, and bortezomib can cause p53-independent
apoptosis in these cell lines. [204] The authors conclude the proteasome may be a good target
in solid epithelial tumors: “In sum, elevated proliferation and metabolic rate resulting from
malignant transformation of the epithelium stresses the [ubiquitin-proteasome pathway] and
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renders ovarian carcinoma more sensitive to apoptosis in response to proteasomal inhibition.”
[204]
Combination studies with bortezomib are also being explored. In pancreatic cancer cell lines,
treatment with bortezomib induced aggresome formation, a cytoprotective response which was
not seen in immortalized human pancreatic epithelial cells or in vivo in mouse pancreatic
epithelial cells. [205] The researchers found that combination therapy with HDAC inhibitors
could disrupt aggresome formation, leading to greatly potentiated apoptotic effects in
pancreatic cancer cells. [205] In prostate cancer patients, researchers used docetaxel and
bortezomib to treat androgen independent prostate cancer. While this therapy was feasible,
tolerable, and showed antitumor activity, it was no more beneficial than monotherapy. [206]
Overall, bortezomib has been very successful in the clinic, making a difference in the lives of
patients. As a first-in-class drug, it has paved the way for the fury of proteasome inhibitors that
have reached investigational new drug (IND) status in the last eight years. However, its clinical
use is strictly limited by dose-dependent severe toxicities, most notably peripheral neuropathy.
Other serious side effects include neutropenia and thrombocytopenia, as well as
gastrointestinal, heart, lung, and liver problems. [196] Therefore, further development of INDs
in this drug class require painstaking safety and efficacy testing in Phase I trials to quantify and
minimize these side effects.
The next proteasome inhibitor to be developed for the clinic came right on the heels of
bortezomib. In 2003, new life was breathed into the β-lactone class of proteasomes inhibitors
with the discovery and characterization of the natural product proteasome inhibitor NPI0052/Salinosporamide A (now called marizomib) (Figure 1.4.B). [207] It was shown to inhibit
the proteasome faster than bortezomib and its inhibition lasted longer as well. [201]
Mechanistically, it appears to cause caspase-4-mediated apoptosis (induced by ER stress) in CLL
cells, even with only a 15 minute drug exposure. [201] Xenograft mouse studies of human
multiple myeloma cells showed reduced tumor size upon treatment with marizomib but no
apparent toxicity. [208] Proteasome inhibition was prolonged in tumors and whole blood but
not in other normal tissues. [208] Additionally, marizomib does not appear to be a substrate of
the major ABC transporters involved in multidrug resistance. [209] There are currently four
open Phase I clinical trials of marizomib. [202]
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At the same time, Millennium was busy designing better boronic acid proteasome inhibitors.
Their next inhibitor was a bit of a surprise, as it was a dipeptidyl boronic acid designed to target
parasitic proteasomes, called MLN-273 (Figure 1.4.A). [210] Work by Millennium and others
attempted to take advantage of small structural differences between human proteasomes and
those from infections organisms to develop a new way to treat these diseases. [210-212] MLN273 preferentially targets Plasmodium species and Mycobacterium tuberculosis proteasomes
over human proteasomes. [210, 211]

In Plasmodium, ubiquitinated parasitic proteins

accumulate and cell death occurs, even in species resistant to current therapies, suggesting
MLN-273 could serve as a novel anti-malarial drug. [210] Studies of MLN-273 bound to the M.
tuberculosis proteasome show a unique binding pocket when compared to human proteasomes;
the M. tuberculosis proteasome is functionally and structurally most similar to the T.
acidophilum proteasome. [211] Currently, there are no clinical trials of MLN-273 in the United
States. [202]
Cephalon, Inc got into the act in 2008 with the publication of their orally available boronic acid
proteasome inhibitor, CEP-18770 (Figure 1.4.A). It preferentially targets the CT-L activity of the
proteasome, but also inhibits some serine proteases at high concentrations. [213] While it has a
similar tissue distribution when compared to bortezomib, it is less cytotoxic to normal human
epithelial cells, bone marrow progenitors, and bone marrow-derived stem cells. [214]
Combination treatment of MM cell lines with CEP-18770 and bortezomib or melphalan gave
synergistic activity and resulted in apoptotic cell death. [215] However, PBMCs were not
affected, even at doses 10-fold above those needed to kill MM cell lines. [215] While CEP-18770
is orally bioavailable in rodents, oral doses are approximately one-third as efficient as
intravenous. [213, 215] Nevertheless, in a MM xenograft model, CEP-18770 gives a higher
complete response rate when compared to bortezomib while causing minimal changes in body
mass. [214] Combination therapy in an in vivo model shows that CEP-18770 chemosensitizes
tumors to bortezomib or melphalan therapy with little tumor progression, change in body
weight, or difference in overall survival when compared to monotherapy. [215] There are
currently three total clinical trials of CEP-18770 in the United States, 2 open trials and one
completed trial. [202]
The next inhibitor developed for the clinic was PR-171 (now called carfilzomib), an epoxyketone
registered by Proteolix, Inc (Figure 1.4.C). Carfilzomib works by binding primarily β5 and β5i and
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inhibiting the CT-L activity of proteasomes in cell lines, patient primary tumor cells (MM, CLL,
AML, NHL, and Waldenstrom’s Macroglobulinemia (WM)), whole blood, and PBMCs. [216-218]
Notably, carfilzomib inhibits other proteasome activities and subunits at higher concentrations;
it may also be a substrate for permeability glycoprotein, a well characterized ABC transporter.
[217] In MM cell lines, carfilzomib induces intrinsic and extrinsic apoptosis as a single agent
while also acting synergistically with dexamethasone. [217] More interestingly, carfilzomib was
still effective in some cell lines which were resistant to other therapeutics (bortezomib,
dexamethasone, or melphalan) as well as in bortezomib-resistant primary cells. [217]
Later studies showed that more specific drugs, which block only β5 or β5i, were not cytotoxic in
MM, PBMCs, leukemia, or lymphoma cell lines but that inhibiting both results in apoptosis. [92]
In combination with bortezomib, carfilzomib was additive or synergistic in WM and B cell
lymphoma (BCL) cell lines, depending on the dose used. [218] As a single agent, carfilzomib
caused apoptosis in WM and BCL cell lines in caspase-dependent and –independent manners.
[218] More recent studies suggest a role for carfilzomib in the treatment of lupus, as it prevents
disease progression in a lupus-prone mouse model. [219]
While there are currently 11 clinical trials of PR-171 open, only one has been published. This
Phase I study determined the maximum tolerated dose of carfilzomib in patients as 15mg/m 2
when treated for five consecutive days followed by nine days rest. [216] Carfilzomib achieved
wide tissue distribution, but the elimination half-life was less than 30 minutes. [216] All patients
reported side effects of therapy, most often Grade I/II gastrointestinal problems. [216] Of the
28 patients treated in this study, four were considered responsive (carfilzomib ≥ 11mg/m2) and
nine had stable disease. [216]
Another epoxyketone proteasome inhibitor was reported in 2007 by us, called UK-101 (Figure
1.4.C). [220] Since previous work had demonstrated that the P2 serine was not critical for the
binding of dihydroeponemycin, derivation at the P1’ and P2 positions of this molecule produced
a library of inhibitors. [220, 221] UK-101 was selected due to its specificity for the β1i subunit of
the immunoproteasome, as no immunoproteasome specific inhibitors had thus far been
developed. In prostate cancer cell lines, UK-101 was able to induce apoptosis, but it did not
inhibit angiogenic sprouting of fibroblasts, a process which relies on the constitutive
proteasome. [220] Later computational modeling of UK-101 bound to β1i suggested the basis
for its specificity was a steric clash between the P1’ group and the binding pocket of β5. [222]
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The work contained within this dissertation builds upon these studies to examine the
importance of β1i for prostate cancer growth, using the PC-3 cell line as a model, and examines
in more detail the binding preferences of the lead β1i inhibitor, UK-101.
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Chapter 2: Specific Aims & Hypotheses
The overall goal of this research is to develop small molecule modulators to utilize as molecular
probes of immunoproteasome function and to explore as therapeutic agents for cancer.
Immunoproteasomes, alternatively composed proteasomes found constitutively in cells of
hematopoietic origin but inducible in other cells types, are not functionally well understood.
While their expression is modulated in a number of disease states, the functional consequences
of these changes in protein levels is not clear. Some cancer cell lines upregulate the expression
of the beta catalytic subunits of the immunoproteasome. [223]

In solid tumors, an

inflammatory microenvironment may induce immunoproteasome expression as well. Studies
suggest that cells which express immunoproteasomes are sensitive to their inhibition, and thus,
immunoproteasome inhibitors could be a viable therapeutic option for certain solid
malignancies. However, no immunoproteasome-specific small molecules were available at the
time this research began, so our ability to elucidate the functional importance of
immunoproteasomes was limited, and inhibiting immunoproteasomes selectively was not
possible.
The approval of the proteasome inhibitor bortezomib (Velcade®) by the FDA for the treatment
of multiple myeloma and refractory mantle cell lymphoma validated the catalytic subunits of the
proteasome as chemotherapeutic targets. However, the clinical utility of bortezomib was
limited by severe systemic toxicity, including dose-limiting peripheral neuropathy, which was
thought to be a class effect of proteasome inhibition. Therefore, the development of more
specific and selective inhibitors gained popularity as a methodology to minimize this toxicity.
Targeting the immunoproteasome was also an attractive strategy, as this proteasome subtype is
not expressed in peripheral nerves and thus immunoproteasome inhibitors were expected to
show milder side effect profiles than bortezomib. Such efforts led to the development of UK101, a β1i-subunit specific inhibitor, in the lab of Dr. Kyung-Bo Kim [220, 223]. UK-101 has
shown an ability to inhibit the proliferation of cancer cells expressing increased levels of β1i
while having a minimal effect on “normal” cells.
The major purpose of the research described herein was to validate the mechanism of action of
UK-101, proposed to be the inhibition of β1i, while simultaneously validating β1i as a
chemotherapeutic target in the PC-3 prostate cancer cell line. Previous work showed that UK-
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101 inhibited β1i via covalent modification, using multiple cancer cells lines, and caused
apoptosis after 48 hours [223]. However, the effects of UK-101 on other cellular proteins were
unknown. Our hypothesis was twofold. First, we hypothesized that the expression and catalytic
activity of β1i is important for the growth and proliferation of the PC-3 cell line. Therefore, we
hypothesized that the apoptotic effect seen upon treatment of PC-3 cells with UK-101 was due
solely to its covalent inhibition of β1i.
Using orthogonal tools to modulate the relative abundance and activity of β1i, we attempted to
validate that the anti-proliferative effects seen upon treatment with UK-101 were due to the
covalent modification of β1i and not other off-target effects. In these same systems, we
examined the effect of modulating the expression of β1i on PC-3 cellular proliferation, to
determine the general feasibility of a β1i-targeting approach in cancer cell lines.

The

methodology utilized to achieve these goals is elucidated in the following aims:
Aim 1: Validate the target of UK-101 in the PC-3 prostate cancer cell line is β1i
Aim 1.1: Using natural inducers of immunoproteasome subunits, determine the relative
sensitivity of PC-3 cells to UK-101.
Aim 1.2: Using RNAi-mediated knock-down of β1i protein levels, determine the relative
sensitivity of PC-3 cells to UK-101.
Aim 1.3: Using biotinylated probes of the proteasome, examine the time- and
concentration-dependent binding pattern of UK-101 in PC-3 cells.
Aim 2: Investigate the importance of β1i expression and function for proliferation in the PC-3
prostate cancer cell line
Aim 2.1: Using a siRNA-mediated knock-down of β1i protein levels, determine the effect
of loss of β1i on the viability of PC-3 cells.
Aim 2.2: Using a plasmid-mediated overexpression of β1i protein levels, determine the
effect of β1i and catalytically inactive β1i on the viability of PC-3 cells.

37

Chapter 3: Materials and Methods
A. Cell culture
The PC-3 prostate cancer cell line was obtained from American Type Culture Collection
(Rockville, MD) and cultured in F-12K medium with 10% fetal bovine serum (Atlanta Biologicals,
Lawrenceville, GA) or 10% Tet system approved fetal bovine serum (Clontech Laboratories Inc.,
Mountain View, CA) in tetracycline repressor transfected cell lines. Antibiotics were used as
part of selection media only, as noted in 3S.
B. Compounds
UK-101 was synthesized following procedures previously reported [220]. Human recombinant
Tumor Necrosis Factor-α (TNF-α) from Escherichia coli (E. coli) was purchased from Sigma
Aldrich (St. Louis, MO). Interferon-gamma was purchased from eBioscience (San Diego, CA).
Bortezomib was obtained from ChemieTek (Indianapolis, IN).

Epoxomicin, eponemycin,

epoxomicin-biotin, eponemycin-biotin, carfilzomib, and YU102 were synthesized as previously
described [191, 194, 221, 224, 225]. Puromycin dihydrochloride was purchased from Sigma
Aldrich, G418 sulfate was purchased from Enzo Life Sciences Inc. (Farmingdale, NY), and Zeocin
was purchased from Invitrogen (Carlsbad, CA).
C. MTS cell viability assay
PC-3 cells were plated at a density of 7,000-8,000 cells/well in a 96-well plate, and allowed at
least 24 hours to attach. The indicated inhibitors were added in increasing concentration and
cells were treated for 48 hours. The percentage of cell survival was determined using the MTS
reagent, CellTiter 96® AQueous One Solution Cell Proliferation Assay (Promega, Madison, WI)
following the manufacturer’s protocol. Briefly, 20µL of MTS reagent were added to cell samples
in 100µl of culture media and incubated for one hour at 37°C. Absorbance was recorded at
490nm wavelength on a microplate reader (FL600; Bio-Tek Instruments, Inc., Winnoski, VT) using
the software KC4 v.2.5 (Bio-Tek Instruments, Inc.). Cell proliferation was determined as a
percentage relative to vehicle treated cells. IC50 values were calculated from sigmoid dose
response curves by the method of nonlinear regression to a logarithmic function using GraphPad
PRISM® (GraphPad Software, Inc, La Jolla, CA). These data represent the average of three or
more replicates with error bars showing the standard error of the mean.
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D. Caspase activity assay
Caspase 3/7, 8, and 9 activities were checked using the appropriate Caspase-Glo® kit for cellbased assays and following the manufacturer’s instructions. Briefly, cells were plated in sterile
white 96 well plates and treated in the same manner as they were for the MTS assay. At the end
of the treatment time, 100µL of the room temperature assay dye was added to each well and
mixed thoroughly (400 rpm for 30 seconds [Caspase 3/7] or two minutes [Caspase 8 & 9]). After
an additional 30 minute incubation, luminescence was measured for each sample using a
Veritas™ Microplate Luminometer (Promega Corp., Sunnyvale CA).

Vehicle control was

arbitrarily assigned a value of one and the fold increase of relative luminescent units was plotted
in GraphPad PRISM® (GraphPad Software, Inc). These data represent the average of three or
more replicates and error bars show the standard deviation.
E. Proteasome cell-based activity assay
PC-3 cells were plated in a white-walled 96-well plate at a density of 8,000 cells per well in 50μL
of media per well. Cells were incubated at 37°C and 5% CO2 for 24 hours prior to treatment with
either vehicle control, inhibitor control (10μM epoxomicin), or increasing concentrations (1μM,
10μM, and 50μM of UK-101; 5nM, 50nM, 500nM of epoxomicin or bortezomib) of proteasome
inhibitors for two hours. Following equilibration to room temperature, 50μL of ProteasomeGlo™ Cell-Based Reagent (Promega) containing the luminogenic proteasome substrate (CT-L, C-L,
or T-L) in the appropriate buffer conditions was added to each well, according to the
manufacturer’s instructions. Samples were mixed on a plate shaker per the manufacturer’s
instructions and incubated at room temperature for ten minutes. Luminescence readings were
then recorded for each sample using a Veritas™ Microplate Luminometer (Promega Corp.). After
subtracting the blank control, values were normalized to vehicle control and graphed in
Microsoft® Excel™ (Microsoft, Redmond, WA). Values represent means and error bars display
standard deviation.
F. Immunoblotting
Whole cell lysates were prepared by incubating cells in non-denaturing lysis buffer (50nM TrisCl, 150mM NaCl, 1% NP-40, 1% Triton X-100, and 1% protease inhibitor cocktail (Sigma-Aldrich))
on ice for one hour. Cells were then centrifuged at 14,000 rpm for ten min at 4°C (Sorvall
Biofuge Primo R, Kendro Laboratory Products, Newtown, CT). Supernatants were collected and
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subjected to protein assay via the method of Bradford using Protein Assay Dye Reagent
Concentrate (Bio-Rad, Hercules, CA). Protein concentrations were determined by a GENESYS 10
spectrophotometer and used to ensure equal protein loading (Thermo Spectronic, VWR,
Arlington Heights, IL). Alternatively, cells were lysed in 1X Passive Lysis Buffer, according to the
manufacturer’s instructions (Promega). Equal volumes were used for blotting, in lieu of protein
assay. All lysates were denatured by addition of 2x Laemmli Sample Buffer (Sigma Aldrich) and
incubation at 100°C for ten minutes.
Subsequently, the denatured lysates were resolved by 12% SDS-PAGE and transferred to PVDF
membranes (Bio-Rad). Membranes were blocked with 5% skim milk (Bio-Rad) or 5% bovine
serum albumin (Sigma-Aldrich) in tris-buffered saline with 0.05% tween-20 (TBST) for one hour
at room temperature with agitation. Appropriate primary antibodies were used to incubate the
membranes overnight at 4oC. *β1i, AbCam (ab78336); β-actin, Novis Biologicals (NB600-501);
GAPDH, Santa Cruz (sc-47724); Ubiquitin, Santa Cruz (sc9133); Myc-Tag (9B11), Cell Signaling
(2276); Streptavidin-HRP, Pierce (21126)]

Secondary antibody incubation was done using

agitation for one hour at room temperature in 3% blocking solution. Finally, Pierce ECL Western
Blotting Detection Reagents (normal or femto) (Thermo Fisher Scientific, Rockford, IL) were used
to visualize protein of interests on film (Thermo Fisher Scientific).
G. Interferon-gamma treatment
PC-3 cells were treated with 100U/mL of IFN-γ or vehicle for 24 hours, then washed and given
fresh media. Cells were harvested at the indicated time points after removing the treatment
media, lysed, and blotted as in 3F. Alternatively, PC-3 cells were treated then subcultured into
96 well plates and treated as in 3C for the MTS assay.
H. Tumor necrosis factor-alpha treatment
PC-3 cells were plated onto p100 dishes and treated continuously with vehicle or 20ng/mL TNF-α
for 72 hours and then subcultured. Cells were treated as in 3C for the MTS cell viability assay.
Cells were also collected from well plates every 24 hours and used for immunoblotting, as in 3F.
I. Immunofluorescence
Coverslips were sterilized with ethanol and UV light in a 35mm dish. For the interferon-gamma
conditions, cells were plated on the dish after pretreatment as indicated. At the end of the
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experiment, cells were fixed with 4% paraformaldehyde in PBS and permeabilized with 0.2%
Triton-X in PBS. Coverslips were then blocked with 10% goat serum (Invitrogen) and 1% BSA in
phosphate buffered saline with 0.05% tween-20 (PBST).

Primary antibody was added in

DakoCytomation Antibody Dilutant with Background Reducing Components at 1:800 (Dako,
Carpinteria, CA). Subsequently, secondary antibodies were added (AF488 (Invitrogen) at 1:1000
and Rhodamin Phallodin (Invitrogen) at 1:1000) in the same antibody dilutant. Coverslips were
washed well in PBST, mounted onto slides with Prolong Gold antifade reagent (Invitrogen), and
allowed to solidify overnight. The next day, the coverslips were sealed and visualized using an
inverted fluorescence microscope (Nikon Ti-U microscope) with NIS Element Research image
analysis software (Nikon, Melville, NY).
J. siRNA
The cells were transfected according to the manufacturer’s instructions using DharmaFECT2®
siRNA transfection reagent (Thermo Fisher Scientific, Lafayette, CO). ON-TARGETplus® siRNAs
were used. The positive control pool was for human GAPD [D-001830-10], the negative control
pool was human non-targeting [D-001810-10], and the test pool was for PSMB9 (β1i) *L-00602300-0005+. Additionally, the four individual oligos were tested from the β1i targeting pool *LU006023-00-0002].
Briefly, PC-3 cells were plated at a density of 20,000 cells per well in a 24 well plate and allowed
24 hours to attach. The siRNA was diluted separately from the DharmaFECT2® and after a five
minute incubation at room temperature the two were combined. They were then allowed to
incubate for an additional 20 minutes prior to the addition of complete media. The final solution
added to the cells contained 100nM siRNA (or 125nM, where indicated) and 0.5µL of
DharmaFECT2® per well. 24 hours post-transfection, the transfection media was removed and
fresh media was added.

Media was refreshed every 24 hours thereafter and cells were

subcultured when the untreated and mock transfected controls reached >70% confluence.
Samples were collected at the time points indicated and subjected to western blotting analysis as
detailed in 3F.
K. Phase contrast microscopy
siRNA treated cells were grown (as above) in well plates and observed every 24 hours prior to
the media change.

The cells were visualized using an inverted microscope (Nikon Ti-U
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microscope) with NIS Element Research image analysis software (Nikon).
L. Cell counting
After trypsinization, each well of cells was resuspended in an equal volume of media. An aliquot
was taken and mixed one to one with trypan blue. 10µL of this cell solution was then added to a
TC10 dual-chamber counting slides, in duplicate, and counted on a TC10™ Automated Cell
Counter (Bio-Rad). The number of live cells per milliliter was used to determine the total live cell
population from each well, and this was plotted using GraphPad PRISM® (GraphPad Software,
Inc). Bars represent means and error bars show standard deviations.
M. Site-directed mutagenesis
Mutagenesis was performed using the Stratagene QuikChange® Site-Directed Mutagenesis Kit
following the manufacturer’s instructions (Agilent Technologies, Santa Clara, CA).

Briefly,

polymerase chain reaction was performed with 5ng of DNA for 18 cycles of denaturation for 30
seconds at 95°C, annealing for 60 seconds at 55°C, and elongation for 300 seconds at 68°C.
125ng

of

primer

was

used

of

the

following

GAAGTCCACACCGGGGCCACCATCATGGCAGTGG-5’

and

sequence:

forward

reverse

3’3’-

CCACTGCCATGATGGTGGCCCCGGTGTGGACTTC-5’. After Dpn I digestion, the plasmid DNA was
transformed into One Shot® TOP10 Competent Cells (Invitrogen) according to the manufacturer’s
instructions and plated on agar. After miniprepping (3N) the mutation was confirmed by
sequencing (Eurofins MWG|Operon, Huntsville, Alabama).
N. Plasmid DNA preparation (Miniprep)
Single colonies from agar plates were picked and incubated overnight in LB media with shaking.
After making glycerol stocks, the media was centrifuged to pellet the bacteria. Using a 5Prime
FastPlasmid™ Mini Kit (Gaithersburg, MD), the cells were lysed and transferred onto spin
columns. After washing, the DNA was eluted; the concentration and purity were checked via a
NanoDrop 2000 Spectrophotometer (Thermo Fisher Scientific).
O. Subcloning
To transfer the β1i gene between plasmids, the enzymes Not I and Kpn I were used to digest the
plasmid DNA for two hours at 37°C (New England Biolabs, Inc., Ipswich, MA). To transfer the 5’
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end of the gene only, which contained the mutated base, Kpn I and Pst I digestion was performed
for two hours at 37°C (New England Biolabs, Inc). The digested DNA was purified with either the
QIAquick PCR purification kit or by running an agarose gel and using the QIAEX II gel extraction
kit, as detailed in 3P. Ligation was performed using the Quick Ligation Kit according to the
manufacturer’s instructions (New England Biolabs, Inc.). Ligated plasmids were transformed into
competent cells and plated on agar, as in 3M, and then miniprepped, as in 3N. To confirm
insertion of the gene prior to sequencing, the miniprep DNA was digested as before, run on an
agarose gel, and stained with ethidium bromide to visual the DNA insert. All DNA plasmids
positive for the insert were sent for sequencing.
P. Digest purification
After digesting DNA without an insert, the QIAquick PCR purification kit was used to purify the
DNA according to the manufacturer’s instructions (QIAGEN, Inc., Valencia, CA). To purify all
other DNA, digestion reactions were separated by agarose gel electrophoresis. The DNA was
excised and weighed, then purified using the QIAEX II gel extraction kit following the
manufacturer’s instructions (QIAGEN, Inc).
Q. Plasmid DNA preparation (Maxiprep)
E. coli were grown from glycerol stocks of sequenced DNA as in 3N and then transferred to large
flasks containing 150mL of LB media to grow with shaking at 37°C overnight. In the morning, the
cells were pelleted and either lysed directly or stored at -20°C until lysis. DNA was purified using
the GenElute™ HP Endotoxin-Free Plasmid Maxiprep Kit according to the manufacturer’s
instructions (Sigma Aldrich). After purification, the DNA concentration and purity was
determined using the NanoDrop 2000 Spectrophotometer (Thermo Fisher Scientific). DNA was
stored at -20°C until transfection.
R. Plasmid DNA transfection
PC-3 cells were plated in six well plates at a density of 200,000 cells per well and allowed to
attach for 24 hours. For each well to be transfected, 3.75µg of DNA was combined with 3.75µL
of Plus™ reagent in media, then this solution was mixed with 3.75µL of Lipofectamine™ LTX in
media according to the manufacturer’s instructions (Invitrogen).

The plating media was

removed and replaced with two milliliters of OptiMEM® media (Invitrogen). A 0.5mL final
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volume of transfection solution was then added to each well, bringing the total volume up to
2.5mL. After 24 hours the transfection media was removed and the cells were subcultured into
p100 dishes with fresh, normal media.
S. Antibiotic selection and clonal expansion
The cells in p100 dishes from 3R were allowed to attach for 24 hours. At 48 hours posttransfection, antibiotic selection began. Every three days new media containing antibiotics was
added to the dishes over a total of two weeks. Based on data from the parental PC-3 cell line,
the following doses of antibiotics were used for selection: puromycin, 0.5µg/mL; G418,
0.5mg/mL; Zeocin, 0.4mg/mL. Cells were then plated into 96 well plates at ten cells per milliliter
of media and grown in selection media for two weeks. Colonies resulting from a single cell were
then subcultured into progressively larger areas under selective pressure. Individual clones were
named and used for tests as described.
T. Colony Formation Assay
Transfected PC-3 cells were plated at low density in six well plates and allowed to attach for 24
hours. Cells were either selected with the appropriate antibiotics, or induced (or not) with
doxycycline (1µg/mL) (Sigma Aldrich). Media was changed every three days, including fresh
drugs. Once visible colonies were observed during media change, cells were washed with saline
and fixed for ten minutes in ice cold methanol. Cells were then stained for ten minutes with a
0.5% (w/v) crystal violet solution in 25% (v/v) methanol in water. Destaining was achieved with
water washing and plates were allowed to dry overnight. Images were obtained using a Xerox
scanner (Xerox Corp., Norwalk, CT) with image refinement in Adobe Photoshop (San Jose,
California).
U. General cell viability assay
PC-3 cells were plated at low density (1,000 cells/well) in a 96-well plate and allowed to attach
for 24 hours. Cells were induced or not with doxycycline (1µg/mL) and at appropriate time
points, the percentage of viable cells was determined using the MTS reagent, CellTiter 96®
AQueous One Solution Cell Proliferation Assay (Promega) according to the manufacturer’s
instructions. Induction media was refreshed every three days. Curves reflect the absorbance of
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the dye at 490nM and represent the number of viable cells per well, averaged, with error bars
representing the standard deviation.
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Chapter 4: Results
A. Proteasome inhibitors: 2009 to the present
In the last three years, a number of new proteasome inhibitors have been developed and many
new discoveries about older proteasome inhibitors have been published. Perhaps the most
significant study in this period was performed by Onyx Pharmaceuticals, the developers of a
number of epoxyketone-based proteasome inhibitors. They definitively addressed the issue of
peripheral neuropathy as a side effect of bortezomib treatment: is it a class effect or a
pharmacophore effect? They found that boronic acids inhibit a variety of serine proteases in
vitro and in vivo (cathepsin G, cathepsin A, chymase, dipeptidyl peptidase II, HtrA2/Omi) at
concentrations near those utilized for proteasome inhibition. [226] As they concluded in this
paper, “Our data are consistent with a model in which bortezomib reduces neurite length by
dual inhibition of the proteasome (resulting in oxidative and proteotoxic stress) and the
neuronal prosurvival protease HtrA2/Omi.” [226]

This demonstrates that peripheral

neuropathy, a side effect seen in approximately 30% of bortezomib patients, is an off-target
effect of the boronic acid pharmacophore, not purely a target-mediated adverse drug reaction.
This study also found that aldehyde inhibitors and epoxyketones do not cause detectable
inhibition of serine proteases. [226] However, another study found more evidence that vinyl
sulfone proteasome inhibitors target cysteine proteases. [227] Kisslev’s group found that
changing the pharmacophore of proteasome inhibitors alone was sufficient to change their
binding preferences. [227] This study and others also demonstrated that, regardless of the
pharmacophore, inhibiting only the CT-L activity of proteasomes is not sufficient to cause an
apoptotic response in cancer cell lines, especially MM. [227-229] Finally, a study in prostate
cancer cell lines showed that proteasome inhibition stimulates an autophagic response which
assists cells in clearing protein aggregates to alleviate proteolytic stress. [230]
A study of bortezomib in breast cancer showed that chronic bortezomib treatment reduces
estrogen receptor-α levels in breast cancer cell lines. [231] Surprisingly, it uncovered a link
between bortezomib treatment and estrogen receptor-α-dependent gene transcription,
whereby bortezomib reduces RNA polymerase II occupancy and reduces the proliferative effects
of estradiol. [231] Bortezomib was also suggested to prevent disease progression in lupusprone mice. [219]
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MLN9708, a boronic acid proteasome inhibitor prodrug which is converted to MLN2238 in
aqueous solution, was the first new proteasome inhibitor reported in the last three years (Figure
4.1.A). [232] It is more highly reversible than bortezomib, dissociating from proteasomes sixfold faster, with greatly improved plasma exposure and tumor distribution in rodent models.
[232] It can be formulated for oral, subcutaneous, and intravenous delivery, and is effective in a
xenograft prostate cancer mouse model. [232] It preferentially inhibits the CT-L activity of
proteasomes, although it also targets the C-L and T-L activities at higher concentrations. [233]
Importantly, it is not seen to inhibit the neuronal prosurvival protease HtrA2/Omi, a major
mediator of bortezomib’s neuropathic side effects. [233] MLN9708 is also able to induce
apoptosis in cell lines, primary cells, and a xenograft model of MM with little apparent toxicity to
PBMCs or mice. [233] As a single agent, MLN9708 increases the survival of xenograft mice when
compared to bortezomib, and it has synergistic effects in combination with lenalidomide, HDAC
inhibitors, or dexamethasone. [233] There are currently eight clinical trials of MLN9708, all of
which are open. [202]
The other important general proteasome inhibitor developed recently is ONX 0912 (PR-047), an
epoxyketone with improved solubility, metabolic stability, and oral bioavailability when
compared to carfilzomib (Figure 4.1.B). [234]

Kinetically, administration resulted in rapid

inactivation of the proteasome systemically, with activity recovering through new proteasome
synthesis in non-blood tissues within 24-72 hours. [234] It promotes antitumor activity in animal
models when provided orally at less than the maximum tolerated dose, reducing tumor size and
improving survival in two mouse models of MM. [234, 235]

ONX 0912 is synergistic in

combination with bortezomib or a pan-HDAC inhibitor, while it has additive effects with
dexamethasone or lenalidomide. [235] There is currently one open Phase I trial of ONX 0912.
[202]
Recently, the development of immunoproteasome inhibitors has been fruitful. Three new
immunoproteasome-selective inhibitors have been published in the last three years, although
no immunoproteasome inhibitors are yet in clinical trials. [202] The first inhibitor is ONX 0914
(PR-957), a β5i selective inhibitor (Figure 4.1.B). In the MOLT-4 human leukemia cell line, ONX
0914 shows a 20- to 40-fold preference for β5i over β1i or β5. [236] Interestingly, selective β5i
inhibition was not found to affect proteasome function, although it does block inflammatory
cytokine production in PBMCs as well as T-cell activation and differentiation. [236] In mice, only

47

Figure 4.1: Proteasome inhibitors (circa 2011). The structures of published proteasome
inhibitors are depicted. A. MLN9708, a prodrug which becomes MLN2238 in solution, is a new
boronic acid pharmacophore containing proteasome inhibitor. B. Epoxyketone proteasome
inhibitors, including the β5i-selective inhibitors, ONX 0914 and PR-924. C. An aldehyde-based β1i
immunoproteasome inhibitor.
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1-10mg/kg of ONX 0914 is necessary to inhibit β5i in the blood and kidney, with good tissue
penetrance and an anti-inflammatory response at one-tenth of the maximum tolerated dose
(30mg/kg). [236] ONX 0914 is also able to protect mice from dextran sulfate sodium-induced
colitis, while a β5-selective inhibitor could not. [237] This suggests that β5i inhibition may be
helpful for inflammatory diseases. Studies found ONX 0914 gave a similar therapeutic response
as entranercept, an anti-tumor necrosis factor-α therapy, and bortezomib in animal arthritis and
colitis models, respectively. [236, 237] Additionally, lupus-prone mice responded well to ONX
0914, showing lesser symptoms due to drug-mediated prevention of disease progression. [219]
Another immunoproteasome selective inhibitor developed in the last three years was PR924/IPSI (Figure 4.1.B). PR-924 is 130-fold selective for β5i over β5, although it does also inhibit
β1i in cells. [92] While β5i is inhibited by doses in the nanomolar range, the viability of tumor
cells and PBMCs is not affected unless micromolar doses are used. [92, 238] MM cells treated ex
vivo with PR-924 had a significant loss of viability, as did mouse xenograft models. [238]
The final immunoproteasome inhibitor reported thus far is IPSI-001, a peptide aldehyde which
inhibits β1i and calpain (Figure 4.1.C). [239] PBMCs and MM cell lines with resistance to
bortezomib are sensitive to IPSI-001, although human umbilical vein endothelial cells are not,
suggesting an improved toxicity profile when compared to bortezomib. [239] Although IPSI-001
lacks the potency necessary for development as a therapeutic agent, it can be used to validate
an immunoproteasome-targeting approach. [239]
B. Aim 1: Validate the target of UK-101 in the PC-3 prostate cancer cell line is β1i
Novel small molecules examined for efficacy as anticancer therapeutics are failing often in
clinical trials. The reason for this attrition has changed significantly in the years between 1991
and 2000. In 1991, PK/bioavailability (40%), efficacy (30%), clinical safety, and toxicology (30%
combined) were the top four reasons for attrition of all drugs in clinical trials. [240] By 2000, the
problem with PK/bioavailability had declined to less than 10%, while problems with efficacy,
clinical safety, and toxicology were as bad as or worse. [240] This strongly suggests that the
methods by which scientists predict which molecules will have success in humans is quite
flawed, resulting in huge expenditures on drugs which eventually fail. A more recent paper on
Phase III and submission failure in 2007-2010 showed that two-thirds of drug failures at this
stage were due to efficacy problems. [241] Additionally, the greatest number of drug failures
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were due to anticancer drugs (n=23, 28%), and the author suggests that many of the oncology
failures were due to assuming success in one tumor type would translate to other tumor types.
[241] All of this points towards the necessity of additional preclinical work to define the
mechanisms of action of new small molecules and to determine a compelling clinical rationale
for their use in any particular type of cancer.
We have undertaken such studies during the development of our β1i inhibitor, UK-101. While
UK-101 causes apoptosis in cancer cell lines, it is not yet clear whether this apoptotic effect is
directly mediated by its irreversible inhibition of β1i. By choosing a sensitive cancer cell line and
conducting all of our experiments within it, we examine the relationship between our drug and
its target while minimizing other confounds. Previous work completed in our lab demonstrated
that treatment of PC-3 cells with UK-101 led to apoptotic cell death at low micromolar
concentrations. [220] Additional work showed that UK-101 modified β1i covalently in PC-3 cells,
and that this covalent modification lasted at least 48 hours. [223] Thus, we chose the PC-3
prostate cancer cell line as our model system. Since off-target effects are major roadblocks for
the development of new and effective pharmaceuticals, target validation studies in this system
will assist in the further progression of β1i inhibitors towards preclinical trials. Our overall
hypothesis is that the apoptosis seen upon treatment with UK-101 is due to the covalent
modification of β1i.
We were interested in examining the sensitivity of the PC-3 cell line to proteasome inhibitors,
including the new immunoproteasome selective inhibitors IPSI (PR-924) and PR-957 (ONX 0914).
As shown in Figure 4.2.A, all seven inhibitors tested are capable of reducing the cell viability of
PC-3 cells. The β5i-targeting selective inhibitors IPSI and PR-957 had IC50 values around 25µM,
while UK-101 had an IC50 between one and five micromolar. This suggests that β1i may be more
important for the viability of PC-3 cells. Alternatively, it could suggest that UK-101 is less
subunit selective than IPSI and PR-957, as it does have a similar IC50 value as eponemycin, from
which it is derived. Additionally, we wanted to examine the apoptotic pathway activated by
treatment with UK-101. We used epoxomicin, the general epoxyketone proteasome inhibitor,
as a positive control. After a 48 hour treatment in PC-3 cells, we found that both proteasome
inhibitors activated all three caspase-types examined (Figure 4.2.B).

This suggests that

proteasome inhibition, whether by epoxomicin or UK-101, activates both the intrinsic and
extrinsic apoptotic pathways.
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Figure 4.2: The effects of proteasome inhibition on the PC-3 prostate cancer cell lines. A. Cells
were treated for 48 hours to determine viability. General proteasome inhibitors such as
bortezomib (Btz), carfilzomib (Cfz), and epoxomicin (Epx) have low nanomolar IC50
concentrations. Eponemycin (Epn) has IC50 values in the high nanomolar range, while UK-101
has values in the low micromolar range. The new immunoproteasome specific inhibitors, IPSI
and PR-957, also have IC50 values in the micromolar range, although higher than UK-101. B.
Caspase activity assays in PC-3 cells after 48 hour incubation with inhibitors. Treatment of cells
with concentrations slightly above the IC50 value for epoxomicin and UK-101 results in activation
of all three caspase activities, confirming the loss of cell viability in A is due to apoptosis.
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Previous work in the lab also showed that UK-101 could inhibit the CT-L activity of purified
proteasomes. [223] We were interested to know whether this was also true for the
proteasomes within the cells. Additionally, we wanted to explore the effect of UK-101 on the
other typical proteasome activities, the C-L and T-L activity. Thus, we treated PC-3 cells with
inhibitor for two hours and checked proteasome activity using a cell-based system, with high
dose epoxomicin serving as a positive control. As expected, bortezomib preferentially targeted
the CT-L activity in cells, although it inhibited the C-L and T-L activities at higher doses (Figure
4.3.A). Epoxomicin, on the other hand, targets all three activities, even at low doses, although
higher doses demonstrate its preference for the CT-L and T-L activities (Figure 4.3.B). There has
been some question as to which proteasome activities β1i is responsible for, as some have
suggested it has C-L activity, similar to its homologue β1, while others have suggested it has
primarily CT-L activity, based on its altered binding pocket. [21, 24, 25] In our cell line, low dose
treatment with UK-101 reduced the CT-L and C-L activities while activating the T-L activity
somewhat (Figure 4.3.C).

This C-L activity inhibition does not change much as the dose

increases, although the CT-L activity does decrease somewhat at the higher doses. If UK-101 is
truly a β1i subunit selective inhibitor, this suggests that β1i is responsible for a significant
amount of the CT-L and C-L activity in PC-3 cells, which would explain their sensitivity to
treatment with this inhibitor. Surprisingly, when one compares the eventual reduction in cell
viability caused by extending these two hour treatments over 48 hours, one finds the lowest
concentration has little to no effect on cell viability, but the next highest concentration affects it
significantly (Figure 4.3.D). In the bortezomib and epoxomicin treated cells, one can see a large
change in the proteasome activity profile between these two treatments. However, there is
little change in the proteasome activity profile for the UK-101-treated cells. The small change
seen may be enough to induce apoptosis in this cell line. However, this may suggest additional
targets for UK-101 which enhance its apoptotic effect.
C. Aim 1.1: Using natural inducers of immunoproteasome subunits, determine the relative
sensitivity of PC-3 cells to UK-101.
Many cytokines, such as tumor necrosis factor-alpha (TNF-α) and interferon-gamma (IFN-γ), are
known to upregulate the levels of the immunoproteasome catalytic subunits, resulting in the
cooperative expression of β5i, β1i, and β2i and their subsequent assembly into
immunoproteasomes [242]. In the case of IFN-γ, this effect is achieved by a type II interferon
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Figure 4.3: The effects of proteasome inhibition on proteasome activity in PC-3 cells. A-C. Cells
were treated with proteasome inhibitors for two hours and then the CT-L, C-L, and T-L activity of
proteasomes from the cells was measured. A. Bortezomib (Btz) treatment decreased all three
proteasome activities at high doses, but preferentially inhibits the CT-L and C-L activities. B.
Epoxomicin (Epx) treatment decreased all three proteasome activities, with little activity
preference, although it is less effective at blocking the C-L activity. C. UK-101 decreases the CT-L
and C-L activities, although it never blocks them completely. It also seems to activate the T-L
activity. D. Cell viability of PC-3 cells treated with these same proteasome inhibitor
concentrations over 48 hours. While partial inhibition of the proteasome is tolerable in these
cells, more significant inhibition of more than one activity at two hours correlates with greatly
reduced viability after 48 hours.
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response utilizing interferon responsive element 1 (IFR1) [243]. For β1i, an additional factor,
signal transducer and activator of transcription 1 (Stat1), binds to the promoter of β1i to
upregulate β1i expression levels [244].
To determine whether IFN-γ could be utilized in this experimental paradigm, PC-3 cells were
treated with increasing concentrations of IFN-γ over 24 or 48 hours and the expression of β1i
was monitored via western blotting. As seen in Figure 4.4.A, a dose of 50U/mL of IFN-γ is
sufficient to upregulate the expression of β1i. These results held whether the treatment time
was 24 or 48 hours.

Importantly, the upregulation of the subunit was shown to be

predominately of the catalytically active form, suggesting that β1i is incorporated into
proteasomes and processed to its catalytically active form within 24 hours of treatment. To
confirm that this upregulation by IFN-γ did not alter the normal expression pattern of β1i,
immunofluorescence was performed. As seen in Figure 4.4.B, even doses of 250U/mL did not
appear to alter the expression pattern of β1i, but simply intensified the signal otherwise
observed.
While these results were greatly encouraging, to perform target validation using the IFN-γ
paradigm, the PC-3 cell expression of β1i would need to be upregulated for at least 72 hours.
Thus, a time-dependent experiment was performed to examine the expression level of β1i after
withdrawal of IFN-γ. A 24 hour pretreatment of 100U/mL of IFN-γ was chosen based upon the
results above as it appeared to cause a significant upregulation of β1i at a minimal dose of IFN-γ.
As seen in Figure 4.4.C, the upregulation of β1i was maintained for at least 96 hours after the
removal of the IFN-γ from the system.
Using this overexpression system, a target validation experiment was performed to test the
effect of IFN-γ-induced β1i overexpression on the sensitivity of PC-3 cells to UK-101. To
determine whether this experimental paradigm affects the sensitivity to PC-3 cells to
proteasome inhibitors in general, epoxomicin was used as a control. Additionally, eponemycin,
which binds to proteasome subunits β1i, β5i, and β5, was included as an additional control.
After pretreatment, cells were placed into 96 well plates and treated with proteasome inhibitors
for 48 hours. Those cells pretreated with DMSO showed comparable IC50 values to those
obtained previously [223]. The cells which had been pretreated with IFN-γ and treated with
epoxomicin or eponemycin did not have any statistically significant changes in cell viability
(Figure 4.4.D). However, those cells pretreated with IFN-γ and then treated with UK-101
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Figure 4.4: Interferon-γ-induced upregulation of β1i affects the sensitivity of PC-3 cells to UK101. A. Treatment of PC-3 cells with increasing concentrations (50 units(U)/mL to 250U/mL) of
IFN-γ for 24 or 48 hours induces a large increase in the expression of β1i. This β1i is found to be
predominately in the catalytically active form. B. The upregulation of β1i expression seen via
western blot is also apparent using immunofluorescence. There appears to be no change in β1i
localization upon induction, or any variation in cellular morphology, even with this high dose
(250U/ml) of IFN-γ. C. Pretreatment with IFN-γ causes a sustained upregulation of β1i protein
levels, lasting at least 96 hours after IFN-γ is removed from the media. D. Based on the
information in C, cells were pretreated with IFN-γ and subcultured in to 96 well plates for the
MTS cell viability assay. A large right hand curve shift is seen in PC-3 cells pretreated with IFN-γ
and exposed to UK-101, which represents a six-fold increase in IC50 value (4µM to 24µM). The
change seen in the eponemycin treatment group fell within the 95% confidence interval of the
nonlinear regression curve fit and thus was not deemed significant.
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showed a six-fold increase in IC50 value (Figure 4.4.D). This suggests that an increase in the
amount of β1i in PC-3 cells significantly impacts the ability of UK-101 to decrease the viability of
these cells. This result supports the hypothesis that UK-101 causes apoptosis in PC-3 cells via its
covalent modification of β1i.
Likewise, TNF-α is also capable of upregulating the expression of β1i, although not as strongly as
IFN-γ. A 72 hour pretreatment was required to sustain β1i upregulation after withdrawal of
TNF-α; expression of β1i decreases over time, nearing basal expression after 72 hours postwithdrawal (Figure 4.5.A). When cells pretreated with TNF-α were then exposed to proteasome
inhibitors, the IC50 values did not change significantly. However, there were some notable
effects at certain concentrations of bortezomib and UK-101 (Figure 4.5.B). TNF-α treatment
appeared to protect bortezomib treated cells from loss of viability, which may be related to one
of its mechanisms of action, proposed to be inhibition of NF-κB. [245, 246] Previous work
showed that TNF-α can induce NF-κB activation in the PC-3 cell line. [223, 247-249] However,
the opposite effect is seen in the UK-101 treated cells, where the cells are more sensitive to UK101 after pretreatment with TNF-α (Figure 4.5.B). This is the opposite of the result we would
expect if the sensitivity to UK-101 was due solely to the expression of β1i. However, both TNF-α
and IFN-γ upregulate other cellular pathways and processes in addition to those of the
immunoproteasome, so further experiments are necessary to definitively address our
hypothesis.
D. Aim 1.2: Using a knock-down of β1i protein levels, determine the relative sensitivity of PC-3
cells to UK-101.
siRNA has quickly become a popular technique for exploring the effects of removing proteins
from cells without many of the issues of temporal control associated with DNA knockouts. Since
the completion of the human genome, siRNA molecules can be designed to knock down almost
any protein. The first group reporting a β1i knock-down, Wang et al, achieved a 70% mRNA
knock-down and a 65% protein knock-down using vector-based siRNA [250]. siRNA against β1i is
commercially available, and one company had a guaranteed knock-down pool. A complete
knock-down of β1i would allow for the determination of the relative proportion of the
antiproliferative effects of UK-101 which do not derive from its binding to β1i.
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Figure 4.5: Tumor Necrosis Factor-α-induced upregulation of β1i affects the sensitivity of PC-3
cells to UK-101. A. Treatment of PC-3 cells with 20ng/mL of TNF-α for 72 hours induces a small
increase in the expression of β1i. This β1i is predominately the catalytically active form and
reduces relatively quickly when TNF-α is removed from the media. B. TNF-α treatment has a
small affect on the sensitivity of PC-3 cells to proteasome inhibitors. Bortezomib seems to be
less effective at 5nM in the TNF-α-treated cells while UK-101 is more effective at 10µM in the
TNF-α-treated cells. However, there is no net change in IC50 value under these conditions.
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We first set out to determine the degree and length of β1i knockdown using pooled siRNA. We
found, similar to a GAPDH positive control pool, reduction in the expression of unincorporated
pre-β1i after 24 hours, suggesting a reduction in newly synthesized β1i protein (Figure 4.6). As
seen with the positive control, β1i siRNA decreased catalytically active β1i protein levels at 48
hours post-transfection, with significant knockdown occurring at 72 hours post-transfection.
This reduction in β1i protein level was maintained up to 168 hours post-transfection. The
scrambled control siRNA pool, which served as a negative control, had no effect on the
expression of β1i or GAPDH. While the β1i protein level was undetectable by western blotting,
some residual protein may have still been expressed in the cells. Nevertheless, this level of
knockdown should be sufficient to see some effect on the sensitivity of transfected cells to UK101.
To test this, we transfected cells with the scrambled control or β1i siRNA pools and tested their
sensitivity to the proteasome inhibitors epoxomicin, eponemycin, and UK-101. The cells were
treated with inhibitor at 96 to 144 hours post-transfection. As shown in Figure 4.7.A, there was
no change in the sensitivity of the transfected cells to any of the inhibitors when comparing the
scrambled control to β1i siRNA groups. This suggests that the effect of UK-101 on cell viability is
not mediated by β1i. However, western blotting is a non-quantitative technique, so while the
protein levels were undetectable using our β1i antibody, perhaps the knockdown did not reduce
the protein levels sufficiently to see an effect. Thus, we transfected the cells using 125nM of
siRNA (instead of 100nM) to look for a relationship between siRNA concentration and sensitivity
to proteasome inhibitors. However, when we treated these cells we also saw no change in
sensitivity to any of our proteasome inhibitors (Figure 4.7.B). This once again suggests an
alternative target for UK-101 which is capable of inducing its antiproliferative effect.
To confirm this result, we transfected the PC-3 cell line with plasmid DNA containing a small
hairpin RNA (shRNA) against β1i and selected for cells which were puromycin resistant. After
two weeks, we obtained pooled knockdown clones which were clonally expanded under
selective pressure from a single cell to create stable cell lines. As shown in Figure 4.8.A, we
tested the knockdown efficacy compared to empty vector transfected cells and selected four
clones of each type to move forward for additional testing. The knockdown efficacy of each
clone differs, thus we expected to see differing effects on the sensitivity of the knockdown
clones to UK-101. However, there was almost no change in the viability of the cells between
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Figure 4.6: siRNA-mediated knockdown of β1i results in loss of protein expression. Western
blotting shows that siRNA-mediated knockdown of the control protein GAPDH and the
experimental protein β1i begins at 48 hours post-transfection and can be maintained for up to
168 hours post-transfection. [UTC = untreated control; M = mock transfected; siG = siRNA
against GAPDH; siC = siRNA scrambled control; siβ = siRNA against β1i+
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Figure 4.7: siRNA-mediated knockdown of β1i does not affect the sensitivity of cells to
proteasome inhibition. MTS cell viability assay between 96 and 144 hours post-transfection. A.
MTS assay from cells treated with 100nM siRNA shows no significant difference between
scrambled control siRNA and β1i siRNA. B. MTS assay results obtained from cells treated with
125nM of siRNA show the same results as in A.
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Figure 4.8: shRNA-mediated knockdown of β1i does not affect the sensitivity of cells to
proteasome inhibition. A. Western blot of β1i expression in single cell clones containing either
the shRNA targeting β1i or the empty vector. Expression of β1i is reduced to varying degrees in
the shβ1i clones. B. MTS assay results obtained from selected clones shows no effect of the
plasmid DNA (black lines, pLKO empty vector; red lines, shβ1i in pLKO vector) on the sensitivity
of cells to UK-101 or other proteasome inhibitors.
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clones (Figure 4.8.B) for any of the proteasome inhibitors examined, including UK-101. This
result, akin to the siRNA data, does not support our hypothesis that UK-101 mediates its
apoptotic effect through the inhibition of β1i.
However, a major drawback of a RNA knockdown approach is the existence of a homologous
protein (β1) which can be substituted in the assembly process for the missing β1i, as β1i serves
as a scaffold protein for the formation of the immunoproteasome complex. As small molecule
inhibitors of β1i do not affect the assembly of proteasomes, but siRNA and shRNA do, knocking
down the protein will not have the same effect as simply inhibiting its catalytic activity. Still, the
sensitivity of PC-3 cells to UK-101 regardless of the expression level of β1i strongly suggests that
the antiproliferative effect mediated by UK-101 is not due solely to its covalent modification of
β1i.
E. Aim 1.3: Using biotinylated probes of the proteasome, examine the time- and
concentration-dependent binding pattern of UK-101 in PC-3 cells.
Epoxyketones are known to be exceptionally specific for the Ntn-hydrolase class of enzymes.
[193] Thus, additional targets of these small molecules are likely to be other proteasome
subunits. Based on the results detailed above, we hypothesized that UK-101 binds proteasome
subunits other than β1i. To test this hypothesis, we utilized a biotinylated probe of the
proteasome, biotin-epoxomicin (Figure 4.9.A) in a competition assay. This is a well established
method of detecting interactions with proteasome subunits by detecting the loss of binding
between the subunit and the biotinylated probe after pretreatment with the compound of
interest.
Using the same two hour treatment as in Figure 4.3, we examined the binding specificity of UK101 over a large range of concentrations. Eponemycin and epoxomicin were used as positive
controls and vehicle was used as a negative control. As seen in Figure 4.9.B there is no change
in the binding pattern of epoxomicin-biotin at doses ranging from 0.1-5µM. However, at 10µM
the strong band representing β5 and β5i diminishes significantly, suggesting that doses at and
above this concentration are not specific for β1i. However, no additional changes in the binding
pattern are seen between ten and fifty micromolar. If the cells were treated with compound for
24 hours, then exposed to biotinylated compound for an additional hour, a different picture
emerges.

As showed in Figure 4.9.C, UK-101 demonstrates a significant degree
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Figure 4.9: Competition assay to determine the proteasome binding specificity of UK-101. A.
The structure of the probe, epoxomicin-biotin. B. The two hour competition experiment shows
loss of specificity at high doses. Cells were pretreated with UK-101, DMSO (D), 1µM epoxomicin
(Epx), or 1µM eponemycin (Epn). At the end of this treatment time, epoxomicin-biotin was
added directly to the media and allowed to incubate for an additional hour. While UK-101
appears to have no effect on the β2 and β2i binding of epoxomicin binding, there is a reduction
in the band intensity for β5/β5i at higher concentrations. C. Cells were treated as in B except
that the first treatment was for 24 hours and the concentration of epoxomicin was reduced to
0.1µM. UK-101 is much less specific after 24 hours of treatment. At doses greater than one
micromolar almost complete competition with the epoxomicin-biotin was observed, suggesting
a significant loss in specificity over time in this continuous treatment paradigm.
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of binding to other proteasome subunits at concentrations as low as 1.25µM. This is near the
IC50 value for UK-101 and suggests that its growth inhibitory effect at 48 hours is likely due to
the inhibition of multiple proteasome subunits.
These data, combined with the other studies detailed above, disprove the hypothesis that UK101 is specific for β1i in the PC-3 prostate cancer cell line. Other groups, using β5 and β5i
selective inhibitors, have recently observed a lack of cytotoxicity at subunit selective
concentrations [92, 236, 238]. This evidence also suggests that the apoptotic effect of UK-101
may be due to the inhibition of multiple proteasome subunits. Thus, we attempted to address
the question of whether β1i alone is a valid chemotherapeutic target by further studies in the
PC-3 cell line.
F. Aim 2: Investigate the importance of β1i expression and function for proliferation in the PC3 prostate cancer cell line
Since our small molecule probe of the β1i subunit is not truly subunit specific, we wanted to use
alternative approaches to examine the importance of the β1i subunit and its catalytic function
for the proliferation of the PC-3 prostate cancer cell line. Thus, we began by examining the
effects of our siRNA model on PC-3 cell viability. Moreover, we produced a number of clonal cell
lines expressing wild type or catalytically inactive β1i to examine its importance for cellular
growth. Some of these clones contain the β1i gene under control of the tetracycline repressor,
allowing us to “turn on” the gene upon addition of tetracycline or doxycycline to the media,
providing temporal control.
With further medicinal chemistry efforts it may well be possible to produce a β1i selective, if not
specific, epoxyketone proteasome inhibitor. However, examining the biological significance of
β1i for the survival of PC-3 cells would provide additional information regarding the utility of a
β1i selective inhibitor and suggest possible screening strategies for use during the validation of
novel small molecule inhibitors of β1i.
G. Aim 2.1: Using a siRNA-mediated knock-down of β1i protein levels, determine the effect of
loss of β1i on the viability of PC-3 cells.
As seen in Figure 4.6, siRNA treatment caused a significant reduction in β1i protein levels which
was maintained over time. During this series of experiments, a difference in the confluence of
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the cells was seen, as shown in Figure 4.10. This somewhat surprising result was observed
repeatedly in a number of independent experiments. There were no apparent differences in
cellular morphology, nor any differences in the number of detached cells between the groups.
Thus, we hypothesized that the expression of catalytically active β1i promotes the proliferation
of PC-3 cells.
To test this hypothesis we first did basic cell counting experiments to determine if this apparent
difference was both real and significant. The first experiment confirmed that siRNA-transfected
cells proliferated more slowly than mock-transfected cells, as expected, and the β1i siRNA
treated cells proliferated more slowly than scrambled control treated cells (Figure 4.11.A). An
independent experiment was performed to assess the significance of the difference in cell
number between the control and knockdown cells, using two-way ANOVA. As shown in Figure
4.11.B, this difference was significant at the later time points of the experiment, with very high
significance at 168 hours post-transfection.
While this exciting result suggested that β1i may play a role in the normal proliferation of PC-3
cells, this may also be due to an off-target effect of the siRNA. The siRNA used in the previous
experiments was comprised of a pool of four independent oligos which all target different
portions of the β1i coding sequence. This is generally accepted as the methodology which
produces the best reduction in protein expression while minimizing off-target effects. [251]
However, if one of these four oligos also had another target within the cell, it could be
responsible for the proliferation change. Thus, we obtained the four individual oligos and tested
them as single agents in our cells. As shown in Figure 4.12.A, all four oligos were able to knock
down protein expression between 96 and 168 hours post-transfection, as was seen with the
pool. When cell counting was performed with these individual oligos, however, none of the
changes in cell number, when compared to the control siRNA, were shown to be statistically
significant using two-way ANOVA (Figure 4.12.B). This suggests that the pooled knockdown
cells, while indistinguishable from the individual oligos via western blotting, may produce a
more complete reduction in protein expression, leading to the observed reduction in
proliferation. We thus began further testing of this proliferation hypothesis.
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Figure 4.10: siRNA-mediated knockdown of β1i appears to affect the growth of PC-3 cells.
Phase microscopy images of PC-3 cells taken at the times indicated post-transfection. There
appear to be fewer cells in the scrambled control siRNA-treated cells were compared to β1i
siRNA-treated cells. Otherwise, there seem to be no changes in cellular morphology between
the groups.
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Figure 4.11: siRNA-mediated knockdown of β1i affects the proliferation of PC-3 cells. Cell
counting of siRNA treated cells. A. Initial cell counting data showed a trend of decreasing cell
number when scrambled control siRNA-treated cells were compared to β1i siRNA-treated cells.
Both appear to have slower growth than mock-transfected cells. B. Cell counting data from a
separate experiment showed that the difference between the scrambled control siRNA-treated
cells and β1i siRNA-treated cells was significant (two-way ANOVA; * indicates p<0.05; ****
indicates p<0.0001).
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Figure 4.12: Individual siRNA oligos knockdown β1i but do not affect the proliferation of PC-3
cells. The individual oligos which made up the siRNA pool were purchased individually and
treated to cells.

A. Western blotting showed that the individual oligos were capable of

significantly decreasing β1i expression over time, similar to the pooled siRNA. B. The individual
oligos did not affect the growth of PC-3 cells in a significant way, as determined by two-way
ANOVA, although the pooled knockdown from 4.11.B did (two-way ANOVA; * indicates p<0.05;
**** indicates p<0.0001).
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H: Aim 2.2: Using a plasmid-mediated overexpression of β1i protein levels, determine the
effect of β1i and catalytically inactive β1i on the viability of PC-3 cells.
Natural inducers, such as IFN-γ and TNF-α, upregulate the expression of many other proteins in
addition to β1i. To isolate the effect of upregulating β1i only, we used a plasmid containing preβ1i, which should be correctly incorporated and activated by normal cellular processes.
Transfection of DNA containing the entire protein, including the propeptide, is preferred over
the mature protein so as to prevent random catalysis reactions and N-terminal acetylation,
which inactivates the enzymatic function of the protein [63].
With this in mind, we utilized a dominant negative construct to replace the normal β1i in
immunoproteasomes. This approach is an effective way to mimic the effects of enzymatic
inhibition by a small molecule. Plasmids which express inactive mutant versions of the
proteasome subunit β1i have been described in the literature [15, 18, 20, 23]. We created wild
type and mutant forms of the β1i gene in two distinct constructs: first in a vector containing a
myc-FLAG tag (Figure 4.13.A) and then in a vector containing the tetracycline operator sequence
(Figure 4.13.B). The myc-FLAG system allows for the rapid detection and isolation of the gene of
interest, although the tag could interfere with the protein’s function. The tetracycline system
allows for the induction or repression of gene expression based on the presence of tetracycline
(or doxycycline) in the media. This is achieved by transfection with the plasmid (pcDNA6/TR)
containing the tet repressor which, in this case, binds to the tetracycline operon in the absence
of tetracycline to repress gene transcription (Figure 4.13.B). The mutant was created via sitedirected mutagenesis and confirmed via sequencing (Figure 4.13.C), with the resulting mutation
at amino acid 21 of the protein, which is amino acid one in the mature protein, as shown in
Figure 4.13.D.
To first ensure the incorporation and activation of β1i, we utilized the myc-FLAG-tagged β1i
plasmids. After transfection and selection with G418 (an aminoglycoside antibiotic similar in
structure to gentamicin) for two weeks, we examined the expression of the myc tag using
western blotting. As shown in Figure 4.14.A, the cells transfected with β1i-myc-FLAG express
two proteins of the expected molecular weight corresponding to the inactive and active tagged
form of β1i.

The cells transfected with β1i-T21A-myc-FLAG, however, show a band of

intermediate size in place of the active tagged form seen with the transfection of the wild type
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Figure 4.13: Vectors and sequences. A & B. The vectors used in the studies to follow. C. DNA
sequencing results showing the correct mutation. D. Translation of the DNA sequence into
protein shows the point mutation results in the correct amino acid change in β1i.
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Figure 4.14: Expression the tagged catalytically inactive mutant of β1i appears to affect the
growth of PC-3 cells. A. Western blot for the myc antibody showing expression of the
unprocessed form of β1i in both the wild type and mutant transfected cells, but not those
transfected with empty vector. The active form of the protein is present in both β1i-transfected
cell types but at different molecular weights, due to changes in the propeptide cleavage. B.
Detection of additional proteasome catalytic subunits and ubiquitin in these transfected cells.
C. Colony formation assay showing a reduction in the ability of the β1i mutant transfected cells
to grow into colonies when plated as single cells.
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protein. This partially processed form should contain approximately nine or ten of the amino
acids from the propeptide sequence, which are not cleaved due to the mutation of the
threonine at amino acid 21 to alanine. [25, 81] Thus, our system is working properly, as both
tagged forms of β1i are being incorporated into proteasomes, as shown by their processing into
smaller proteins.
Further examination of these pooled cell populations showed no changes in overall levels of
ubiquitin (Figure 4.14.B). However, there was a notable decrease in the expression of β5 in the
cells transfected with the mutant β1i DNA (Figure 4.14.B).

This may reflect increased

proteasome turnover in these cells, as they attempt to compensation for the mutation in β1i
which renders it catalytically inactive. There appears to be a slight increase of β5i expression in
the β1i wild type and mutant transfected cells, as would be expected if the expression of β1i in
the cells was increased (Figure 4.14.B).
Interestingly, after transfection and selection with antibiotics we found that there were many
fewer surviving cells of the β1i-T21A-myc-FLAG variety than in the transfection with wild type
β1i or empty plasmid DNA. We therefore took these pooled populations of selected cells and
did a colony formation assay. As is shown in Figure 4.14.C, fewer colonies were seen in the
mutant-transfected cell than the wild type or empty vector cells. These data suggest that
constitutive expression of the catalytically inactive β1i mutant is detrimental to PC-3 cell
proliferation.
To further test this hypothesis, we decided to use an inducible expression system, which would
allow us to control the expression of the β1i gene using tetracycline or doxycycline. This would
allow for the unbiased selection of cells containing the plasmid DNA rather than favoring the
selection of cells which are resistant to the potential growth inhibitory or dependent on the
growth stimulatory effects of the expressed gene. After creating stable cell lines expressing the
tetracycline repressor protein using blasticidin and clonal expansion, we retransfected these
cells with the β1i plasmids. We then selected these plasmids using zeocin, which is on its own
promoter, and concurrently did a colony formation assay (Figure 4.15.A). This assay showed a
great reduction in the number of colonies formed in the mutant cells which were induced when
compared to their uninduced controls. Prior to clonal expansion, we did additional colony
formation assays on the pooled cell populations by treating with or without doxycycline
(compare bottom rows of Figure 4.15.B and 4.15.C). In this case, the number of colonies formed
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Figure 4.15: Expression the inducible catalytically inactive mutant of β1i appears to affect the
growth of PC-3 cells. A. Colony formation assay during antibiotic selection of cells transfected
with the tetracycline repressor protein and β1i wild type or mutant. Those cells selected with
doxycycline in the media and the wild type protein have similar numbers of colonies while those
with the mutant protein have few to no colonies. B. Pooled selected cells expressing wild type
β1i were exposed to doxycycline or not until visible colonies were observed. The number and
appearance of the colonies is less in the doxycycline-treated group. C. Pooled selected cells
expressing mutant β1i were treated as in B. They show fewer colonies in the doxycycline
treated group.
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was more equal between the uninduced conditions. However, when the mutant β1i was
expressed, there were fewer colonies seen and those observed appeared to be smaller than the
uninduced control cells (Figure 4.15.C). The induction of wild type β1i also appeared to reduce
the formation of colonies somewhat, although not as severely as the mutant (Figure 4.15.B).
Thus, we decided to once again proceed with clonal expansion, so we could test the degree of
induction with doxycycline against the proliferation rates of the cells.
Some of the clones generated were then tested for their ability to induce the expression of β1i.
As shown in Figure 4.16.A, both clones were able to effectively induce expression of β1i after 24
hours at all doses of doxycycline tested. Additionally, this change in β1i expression had no effect
on the levels of polyubiquitinated proteins in the cells. These two colonies were also tested to
determine the effects of prolonged β1i induction on cellular proliferation. As shown in Figure
4.16.B, wild type β1i promoted the growth of the clone from Figure 4.16.A. Conversely, the
mutant β1i did not promote the growth of the second clone from Figure 4.16.A; it actually
appears to hamper the proliferation of this line somewhat (Figure 4.16.C). In the other clones
tested, those which grew well showed similar trends as the clones depicted, although in many
cases the differences were not significant due to a high level of variability between replicate
wells.
Additionally, during this series of experiments we also transfected cells on a β1i-reduced
background. However, we observed much more rapid growth in cells expressing β1i and
transfected with these plasmids than in those that did not express much β1i. Thus, the data
depicted here are cells grown on a parental background, which express a moderate level of β1i
and are responsive to changes in β1i expression levels. Overall, these results suggest that β1i
may be important for the proliferation of PC-3 cells. Further work is warranted to examine the
generalizability of this response and further characterize the clones reported here.
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Figure 4.16: Expression of wild type β1i increases cellular proliferation while expression of the
catalytically inactive mutant of β1i appears to decrease the growth of PC-3 cells. A. Western
blotting from two clones of the same background, with the blot on the left having wild type β1i
and the blot on the right having mutant β1i. The intermediate size of the partially processed
mutant is shown on the right.

Both clones give high induction of β1i upon addition of

doxycycline with no change in the levels of polyubiquitinated proteins. B. Cell viability (MTS)
assay with the wild type clone from A. Treatment with doxycycline (to induce expression of β1i)
resulted in higher cell proliferation when compared to vehicle control. C. Cell viability (MTS)
assay with the mutant clone from A. Treatment with doxycycline resulted in a slight decrease in
cellular proliferation when compared to vehicle control.
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Chapter 5: Conclusions & Discussion
A: Conclusions
The data described herein examine the utility of a β1i-targeting approach in prostate cancer.
Using a small molecule inhibitor of the β1i subunit of the immunoproteasome, we began by
examining its general effects on the PC-3 prostate cancer cell line. UK-101 caused apoptotic cell
death in PC-3 cells after 48 hours (Figure 4.2) and likewise partially inhibited the proteasome
after two hours (Figure 4.3). These data are complementary to and in line with previous work
completed in our lab. [220, 223] They suggest that a β1i-targeting approach using UK-101 is a
potential therapeutic strategy in prostate cancer.

Since the development of novel

chemotherapeutics is often hindered by off-target effects, we decided to utilize a target
validation approach to confirm that UK-101 induces apoptosis through the covalent
modification and inhibition of β1i. Thus, we began by examining the effects of modulating the
expression of β1i on the sensitivity of PC-3 cells to UK-101.
First we examined natural inducers of the immunoproteasome, INF-γ (Figure 4.4) and TNF-α
(Figure 4.5). Utilizing these cytokines is beneficial in that they are physiologically normal ways
to cooperatively upregulate the expression of immunoproteasome catalytic subunits and ensure
their maturation into fully functional proteasomes. However, these cytokines also have other
cellular targets and effects, so information obtained in these experimental paradigms requires
additional independent validation. Surprisingly, these two natural inducers gave opposite
results, with the IFN-γ treated cells showing less sensitivity to UK-101 and the TNF-α treated
cells showing more sensitivity to UK-101. This was our first indication that UK-101 may be acting
on targets in addition to β1i.
To investigate this discrepancy, we utilized an opposing approach, reducing β1i expression
levels.

Then we examined the effect of treating these PC-3 cells with UK-101.

Two

complementary approaches were employed: a transient knockdown of β1i levels using siRNA
(Figures 4.6 and 4.7) and a stable knockdown of β1i levels using shRNA (Figure 4.8). The major
limitation of this approach was the dual functionality of the β1i protein, since it operates in both
a proteolytic and scaffolding role for immunoproteasomes.

Nevertheless, reducing the

expression of β1i using either of these methods had no effect on the sensitivity of cells to UK101. This was in direct conflict with our hypothesis and suggested that we should more directly
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probe the interaction of this epoxyketone with other proteasome beta catalytic subunits, the
most probable alternative targets for UK-101.
Thus, we examined the binding of UK-101 over two hours and 24 hours using the probe
epoxomicin-biotin and found vastly different results (Figure 4.9). While the binding of UK-101 at
two hours is relatively specific when examining physiologically relevant doses, after 24 hours
this selectivity vanishes and loss of the β5/β5i band is observed.

However, a molecular

modeling study suggested that the tert-butyldimethylsilyl (TBDMS) group of UK-101 would have
a strong steric clash with the S1 binding pocket of β5 [222]. This suggests that the molecule
itself may change under prolonged exposure to aqueous conditions and cellular proteases.
With the specificity issue resolved, we moved forward to determine whether additional
medicinal chemistry efforts to improve the stability and selectivity of UK-101 would provide a
potential therapeutic molecule or simply a good molecular probe. We began by reexamining
the siRNA model, in which we had observed an effect of β1i knockdown on cellular proliferation
(Figure 4.10). Further experiments determined this effect to be statistically significant (Figure
4.11) and not due to a single oligo (Figure 4.12). However, it was impossible to determine using
this approach whether the effect on cell proliferation was due to loss of the protein’s catalytic
function or loss of the protein’s scaffolding function. Thus, we set out to examine the effect of
introducing a catalytically inactive version of β1i into our cells.
The initial approach utilized was to transfect a tagged version of the wild type and mutant β1i to
determine the extent to which β1i would be incorporated into proteasomes in the PC-3 cells.
Incorporation of these tagged proteins would validate this approach, and lack of incorporation
would suggest the necessity of removing the endogenous protein prior to replacement with the
exogenous protein. Fortunately, the wild type and mutant proteins incorporate well (Figure
4.14) and we were pleasantly surprised to note the difficulty in culturing cells containing the
mutant β1i. This suggested that it was the catalytic activity of β1i, rather than its structural
function, which was driving the decreased cellular proliferation seen in Figures 4.10 and 4.11. It
is difficult to do extensive experiments on cells which do not grow well and doing so is a
selective process of its own. Therefore, we decided to place our β1i genes into an inducible
expression vector, to complete the selection process without the confound of β1i gene
expression enhancing or repressing cellular proliferation.
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Once cell lines had been produced which stably expressed the tetracycline repressor, they were
transfected with the inducible β1i expression plasmids. Induction of wild type gene expression
during the selection process was a slight benefit while induction of mutant gene expression was
detrimental to the cells (Figure 4.15). After selection, it was interesting to note that the pooled
mutant cells displayed smaller colony sizes in general when compared to the wild type pooled
cells, possibly due to leakiness of the repression system. Stable clones developed from these
pooled cells were tested and found to rapidly and efficiently induce high levels of β1i expression
when compared to endogenous β1i (Figure 4.16). This induction did not affect the overall levels
of polyubiquitinated proteins. Clones also showed a similar trend in proliferation with and
without induction as was seen in the pooled cell lines, with expression of wild type β1i being
beneficial and expression of mutant β1i being neutral or detrimental (Figure 4.16).
These studies demonstrate that inhibition of β1i, whether chemically or genetically, has an
impact on cellular proliferation. It is important to note this effect on proliferation is only seen
after prolonged loss of β1i catalytic activity. Thus, small molecules which selective inhibit β1i
may not have any effect after the short times normally examined, nor may they actually cause
apoptotic cell death. Rather, it appears such molecules may function as growth inhibitory drugs
for those cells which express β1i, assuming that near continuous inhibition is feasible over such
long periods of time. A similar lack of apoptotic response was found when β5 or β5i selective
inhibitors were tested in MM cell lines [92, 236]. This suggests that subunit specific proteasome
inhibition may have unique characteristics, such as a lack of general cytotoxicity normally seen
with less selective proteasome inhibitors. Future efforts to develop such subunit selective
inhibitors should take these factors into account and not disregard small molecules which fail to
quickly induce apoptosis.
The effects of catalytically inactive β1i are radically different than the characteristic effects of
general proteasome inhibitors, or even activity-specific inhibitors. This suggests that, as noted
above, subunit specific inhibitors will have unique functional effects, both in vitro and in vivo.
Such a finding is exciting, as much remains to be understood in regards to the complex
functional roles of individual catalytic beta subunits, but this implies that each catalytic subunit
may have a distinct and meaningful role in normal and disease states. Thus, efforts to develop
more selective and potent inhibitors of single proteasome catalytic subunits will assist in
addressing such questions and should be encouraged.
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B: Future Directions
Taken as a whole this work suggests that it is the catalytic activity of β1i which confers growth
enhancing effects in PC-3 cells. It is important that further efforts examine the generalizability
of this finding, especially between cancer cell lines or types. Additionally, examining the effects
of β1i expression in in vivo cancer models would shed additional light on the clinical relevance of
these findings and speak to β1i inhibition as a potential chemotherapeutic strategy. One way to
do this would be by the development of fluorescent, luminescent, or near-infrared probes.
Work is underway in the lab to do this using our lead compounds, although validation of these
probes is still in the early stages.
The limitations of our small molecule inhibitor are not entirely surprising. Eponemycin, the
parent compound of UK-101, binds preferentially to β1i, β5, and β5i, as UK-101 appears to do
after 24 hours (Figure 4.9) [190, 191]. Thus, a simple in vivo deprotection of the P1’ alcohol in
UK-101 or cleavage of this bond by an esterase may be responsible for the loss of specificity of
UK-101 over time. This suggests that derivation at the P1’ position to remove the ester linkage
while maintaining the overall structural bulk of the TBDMS group may improve the specificity of
the compound significantly and should be explored in the future.

However, additional

validation work must be completed with any such new compound to ensure a lack of off-target
effects.
Additionally, future medicinal chemistry efforts may benefit from exploring non-peptidic
inhibitors, to alleviate additional proteolytic mechanisms of inhibitor inactivation. A
collaboration with Dr. Chang-Guo Zhan has begun with the virtual screening of a library of
approximately 250,000 small molecules to look for alternative chemical scaffolds which function
as proteasome inhibitors. The ~200 lead compounds have already been selected and tested for
their ability to selectively inhibit the immunoproteasome in the lab, utilizing purified
proteasomes in an in vitro assay, and future work will involved cellular-based methods to
confirm efficacy and examine permeability in cell line systems. Derivations of these novel
scaffolds to produce selective proteasome inhibitors should improve in vivo stability by
minimizing or removing the susceptibility of proteasome inhibitors to protease cleavage, an
issue which currently limits the plasma half-life of carfilzomib to about 30 minutes [216].
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Further studies to characterize the clones which express the inducible wild type and mutant β1i
would allow for the examination of the downstream effects of loss of β1i function. We currently
have no information regarding what occurs between proteasome inhibition and apoptosis, and
this mutant induction system would allow one to address such questions without concerns
regarding off-target effects of the treatment. This system can also quickly be utilized in other
cell lines to examine the effects of inhibiting β1i, at least until a truly selective small molecule
can be developed. Overall, these sorts of studies should also provide a more compelling
rationale for the development of new molecular probes which selectively target β1i.
This inducible approach could also be used to examine mechanisms of resistance to β1i
inhibition by comparing those clones which show growth inhibition upon induction of the
mutant β1i with those that do not. Additionally, clones have been generated which are resistant
to the effects of the tagged mutant, and these cells could likewise be compared to the vector
and wild type clones to examine mechanisms of resistance to proteasome inhibition. This
intrinsic resistance to partial inhibition of the proteasome is a problem clinically, and efforts to
elucidate the mechanisms behind this resistance are underway in our lab and others.
As one potential mechanism of resistance to proteasome inhibitors is changes in proteasome
subunit composition, the tagged β1i can also be used to quickly purify proteasomes from cells
which are sensitive or resistant to partial proteasome inhibition. Since we have made no
attempt thus far to determine the composition of the proteasomes in which our exogenous β1i
is contained, such an approach will provide additional information regarding the cooperative
assembly hypothesis, and possibly also provide purified intermediate proteasomes to test. This
experimental approach could clarify and expand upon the western blotting results in Figure 4.14
and thus may be of interest for future studies.
The field of proteasome biology has come a long way from the days in which proteasomes were
regarded as general garbage disposals, undruggable and uninteresting. As chemists develop
more potent and selective inhibitors, biologists will continue to use them to make important
discoveries which elucidate the functional complexity of the ubiquitin-proteasome pathway.
Many unique roles of the proteasome and its catalytic subunits remain to be discovered, as we
have barely begun to take into account the structural and functional intricacies of these
complexes. Overall, the β1i-targeting approach remains promising, although there is much work
left to be done to move it forward into preclinical development.
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